brain	2981413	1956	Libermann TA	Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.	Nature	1985	263
brain	7585629	1956	Moscatello DK	Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.	Cancer research	1995	118
brain	9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
brain	10202547	1956	Hatten ME	Central nervous system neuronal migration.	Annual review of neuroscience	1999	158
brain	10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
brain	11283316	1956	Wechsler-Reya R	The developmental biology of brain tumors.	Annual review of neuroscience	2001	101
brain	11431323	1956	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	86
brain	11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
brain	14638850	1956	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	122
brain	15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
brain	16624948	1956	Almeida CG	Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.	The Journal of neuroscience 	2006	75
brain	16912159	1956	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	96
brain	16931954	1956	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	68
brain	17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	195
brain	17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
brain	17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
brain	18362333	1956	Diehn M	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.	Proceedings of the National Academy of Sciences of the United States of America	2008	85
brain	18403491	1956	Sampson JH	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.	Neuro-oncology	2008	54
brain	18421051	1956	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	97
brain	18425114	1956	Al-Nedawi K	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.	Nature cell biology	2008	350
brain	18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
brain	18829483	1956	Lo HW	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.	Clinical cancer research 	2008	65
brain	18936474	1956	Heymach JV	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	56
brain	19075262	1956	Prados MD	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.	Journal of clinical oncology 	2009	88
brain	19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
brain	19176518	1956	Fan QW	EGFR signals to mTOR through PKC and independently of Akt in glioma.	Science signaling	2009	60
brain	19204207	1956	van den Bent MJ	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.	Journal of clinical oncology 	2009	110
brain	19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
brain	19252415	1956	Golding SE	Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.	Cancer biology and therapy	2009	49
brain	19412429	1956	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	48
brain	19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
brain	19433789	1956	O'Keeffe GC	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
brain	19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
brain	19920198	1956	Gravendeel LA	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.	Cancer research	2009	128
brain	19960228	1956	Peereboom DM	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.	Journal of neuro-oncology	2010	57
brain	20113523	1956	Ren Y	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.	BMC cancer	2010	47
brain	20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
brain	20150372	1956	Raizer JJ	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.	Neuro-oncology	2010	56
brain	20515495	1956	Krakstad C	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Molecular cancer	2010	65
brain	20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
brain	20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
brain	20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
brain	20679611	1956	Yap TA	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.	Journal of clinical oncology 	2010	77
brain	20716591	1956	Sathornsumetee S	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.	Neuro-oncology	2010	48
brain	20921459	1956	Sampson JH	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	184
brain	21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
brain	21189092	1956	de Boer RA	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.	Annals of medicine	2011	74
brain	21471286	1956	Hegi ME	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.	Molecular cancer therapeutics	2011	35
brain	21610077	1956	Kinney SM	Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes.	The Journal of biological chemistry	2011	46
brain	21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
brain	21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
brain	22025148	1956	Lai A	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.	Journal of clinical oncology 	2011	91
brain	22065080	1956	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	44
brain	22127113	1956	Brand TM	The nuclear epidermal growth factor receptor signaling network and its role in cancer.	Discovery medicine	2011	51
brain	22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
brain	22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
brain	22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
brain	22588883	1956	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	73
brain	22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
brain	22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
brain	22801742	1956	Doecke JD	Blood-based protein biomarkers for diagnosis of Alzheimer disease.	Archives of neurology	2012	65
brain	22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
brain	22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
brain	22964225	1956	Johnson H	Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.	Molecular and cellular proteomics 	2012	30
brain	23070115	1956	Uchida H	Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.	Molecular therapy 	2013	26
brain	23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
brain	23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	36
brain	23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
brain	23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
brain	23401448	1956	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	27
brain	23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
brain	23707073	1956	Babic I	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.	Cell metabolism	2013	30
brain	23964022	1956	Giachino C	Molecular diversity subdivides the adult forebrain neural stem cell population.	Stem cells	2014	24
brain	24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
brain	24135280	1956	Fan QW	EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.	Cancer cell	2013	50
brain	24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
brain	24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
brain	24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
brain	24470557	1956	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	23
brain	24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
brain	24553385	1956	Bettegowda C	Detection of circulating tumor DNA in early- and late-stage human malignancies.	Science translational medicine	2014	385
brain	25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
brain	25080476	1956	Müller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
brain	25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
brain	25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
brain	25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
brain	25586468	1956	Schuster J	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.	Neuro-oncology	2015	54
brain	25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
brain	26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
brain	26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
brain	26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	51
brain	26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
brain	26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
brain	26874901	1956	Chan A	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2016	13
brain	26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
brain	26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
brain	27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
cancer	1557402	1956	Wong AJ	Structural alterations of the epidermal growth factor receptor gene in human gliomas.	Proceedings of the National Academy of Sciences of the United States of America	1992	188
cancer	2981413	1956	Libermann TA	Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.	Nature	1985	263
cancer	3477813	1956	Wong AJ	Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.	Proceedings of the National Academy of Sciences of the United States of America	1987	173
cancer	3798106	1956	Slamon DJ	Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.	Science	1987	1881
cancer	6157683	1956	Ushiro H	Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.	The Journal of biological chemistry	1980	190
cancer	6320011	1956	Downward J	Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.	Nature	1984	417
cancer	6328312	1956	Ullrich A	Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.	Nature	1984	491
cancer	7585629	1956	Moscatello DK	Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.	Cancer research	1995	118
cancer	8339264	1956	Grandis JR	Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.	Cancer research	1993	154
cancer	9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
cancer	9041202	1956	Relf M	Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.	Cancer research	1997	128
cancer	9403702	1956	Petit AM	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.	The American journal of pathology	1997	115
cancer	9625170	1956	Rubin Grandis J	Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.	Journal of the National Cancer Institute	1998	198
cancer	9815926	1956	Goldstein NI	Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.	Clinical cancer research 	1995	117
cancer	9831867	1956	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	109
cancer	10075741	1956	Biscardi JS	c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.	The Journal of biological chemistry	1999	174
cancer	10722725	1956	Jo M	Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.	The Journal of biological chemistry	2000	104
cancer	10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
cancer	10760290	1956	Grandis JR	Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2000	149
cancer	10815932	1956	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	107
cancer	10873065	1956	Huang SM	Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.	Clinical cancer research 	2000	98
cancer	11156248	1956	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	94
cancer	11156523	1956	Harari D	Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.	Oncogene	2000	118
cancer	11283316	1956	Wechsler-Reya R	The developmental biology of brain tumors.	Annual review of neuroscience	2001	101
cancer	11420660	1956	Garcia R	Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.	Oncogene	2001	164
cancer	11426640	1956	Mendelsohn J	The EGF receptor family as targets for cancer therapy.	Oncogene	2000	206
cancer	11431346	1956	Viloria-Petit A	Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.	Cancer research	2001	110
cancer	11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
cancer	11585753	1956	Moasser MM	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	Cancer research	2001	87
cancer	11595683	1956	Ciardiello F	A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.	Clinical cancer research 	2001	135
cancer	11597398	1956	Yarden Y	The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.	European journal of cancer	2001	296
cancer	11597399	1956	Nicholson RI	EGFR and cancer prognosis.	European journal of cancer	2001	363
cancer	11897506	1956	Filardo EJ	Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer.	The Journal of steroid biochemistry and molecular biology	2002	91
cancer	11948098	1956	Buettner R	Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.	Clinical cancer research 	2002	265
cancer	12124174	1956	Liu D	EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.	Cancer cell	2002	103
cancer	12183421	1956	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	158
cancer	12214266	1956	Xia W	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Oncogene	2002	161
cancer	12359858	1956	Wang F	Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.	Journal of the National Cancer Institute	2002	111
cancer	12384534	1956	Wakeling AE	ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.	Cancer research	2002	132
cancer	12429632	1956	Di Lorenzo G	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.	Clinical cancer research 	2002	88
cancer	12435727	1956	Andl CD	Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo.	The Journal of biological chemistry	2003	90
cancer	12499279	1956	Ang KK	Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.	Cancer research	2002	224
cancer	12648469	1956	Holbro T	The ErbB receptors and their role in cancer progression.	Experimental cell research	2003	151
cancer	12717449	1956	Smith LL	Telomerase modulates expression of growth-controlling genes and enhances cell proliferation.	Nature cell biology	2003	107
cancer	12743152	1956	Cohen EE	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2003	98
cancer	12824187	1956	Buchanan FG	Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.	The Journal of biological chemistry	2003	104
cancer	12845624	1956	Witton CJ	Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.	The Journal of pathology	2003	129
cancer	12860957	1956	Mendelsohn J	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.	Journal of clinical oncology 	2003	184
cancer	12953099	1956	Hirsch FR	Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.	Journal of clinical oncology 	2003	238
cancer	14570950	1956	Kris MG	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.	JAMA	2003	389
cancer	14583498	1956	Shinojima N	Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.	Cancer research	2003	158
cancer	14638850	1956	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	122
cancer	14641026	1956	Fischer OM	EGFR signal transactivation in cancer cells.	Biochemical Society transactions	2003	95
cancer	14701768	1956	Soulieres D	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.	Journal of clinical oncology 	2004	145
cancer	14744244	1956	Holbro T	ErbB receptors: directing key signaling networks throughout life.	Annual review of pharmacology and toxicology	2004	147
cancer	14769856	1956	Liu H	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.	The Journal of cell biology	2004	93
cancer	14993230	1956	Saltz LB	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.	Journal of clinical oncology 	2004	287
cancer	15057284	1956	Qian X	E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.	The EMBO journal	2004	106
cancer	15059883	1956	Nahta R	The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.	Cancer research	2004	112
cancer	15084238	1956	Arpino G	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.	Breast cancer research 	2004	105
cancer	15118073	1956	Lynch TJ	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2004	2246
cancer	15118125	1956	Paez JG	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.	Science	2004	1965
cancer	15158434	1956	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	70
cancer	15226328	1956	Xiong HQ	Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.	Journal of clinical oncology 	2004	91
cancer	15269313	1956	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	891
cancer	15310767	1956	Pérez-Soler R	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.	Journal of clinical oncology 	2004	151
cancer	15328174	1956	Nielsen TO	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.	Clinical cancer research 	2004	595
cancer	15329413	1956	Pao W	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2004	999
cancer	15345710	1956	Laederich MB	The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.	The Journal of biological chemistry	2004	75
cancer	15492241	1956	Tracy S	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.	Cancer research	2004	86
cancer	15598946	1956	Spano JP	Impact of EGFR expression on colorectal cancer patient prognosis and survival.	Annals of oncology 	2005	70
cancer	15623594	1956	Huang SF	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.	Clinical cancer research 	2004	78
cancer	15665299	1956	Amann J	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.	Cancer research	2005	98
cancer	15665312	1956	Lo HW	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.	Cancer research	2005	92
cancer	15677699	1956	Chung KY	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.	Journal of clinical oncology 	2005	200
cancer	15681531	1956	Marchetti A	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.	Journal of clinical oncology 	2005	149
cancer	15684311	1956	Spector NL	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.	Journal of clinical oncology 	2005	82
cancer	15709185	1956	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	94
cancer	15710947	1956	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	135
cancer	15728811	1956	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	832
cancer	15731348	1956	Engelman JA	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.	Proceedings of the National Academy of Sciences of the United States of America	2005	148
cancer	15735034	1956	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	82
cancer	15737014	1956	Pao W	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.	PLoS medicine	2005	871
cancer	15738541	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	175
cancer	15741570	1956	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	439
cancer	15746047	1956	Heimberger AB	Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.	Clinical cancer research 	2005	134
cancer	15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
cancer	15753462	1956	Herbst RS	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	86
cancer	15767641	1956	Pao W	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.	Journal of clinical oncology 	2005	94
cancer	15814656	1956	Shimizu M	(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.	Clinical cancer research 	2005	65
cancer	15833866	1956	Chinnaiyan P	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).	Cancer research	2005	84
cancer	15863375	1956	Moroni M	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.	The Lancet. Oncology	2005	197
cancer	15864276	1956	Hynes NE	ERBB receptors and cancer: the complexity of targeted inhibitors.	Nature reviews. Cancer	2005	833
cancer	15870435	1956	Cappuzzo F	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.	Journal of the National Cancer Institute	2005	311
cancer	15886310	1956	Jänne PA	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.	Journal of clinical oncology 	2005	82
cancer	15920544	1956	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	76
cancer	15939921	1956	Baselga J	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.	Journal of clinical oncology 	2005	77
cancer	15955900	1956	Burris HA 3rd	Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.	Journal of clinical oncology 	2005	123
cancer	15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
cancer	15994331	1956	Clayton AH	Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis.	The Journal of biological chemistry	2005	82
cancer	15994928	1956	Zhao X	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.	Cancer research	2005	120
cancer	15998907	1956	Takano T	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	139
cancer	16014882	1956	Shepherd FA	Erlotinib in previously treated non-small-cell lung cancer.	The New England journal of medicine	2005	1010
cancer	16014883	1956	Tsao MS	Erlotinib in lung cancer - molecular and clinical predictors of outcome.	The New England journal of medicine	2005	312
cancer	16020518	1956	Means AL	Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.	Development	2005	106
cancer	16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
cancer	16043828	1956	Eberhard DA	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	Journal of clinical oncology 	2005	344
cancer	16043829	1956	Herbst RS	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2005	275
cancer	16051952	1956	Cappuzzo F	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.	Journal of clinical oncology 	2005	69
cancer	16051966	1956	Peréz-Soler R	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?	Journal of clinical oncology 	2005	70
cancer	16061871	1956	Schilder RJ	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.	Clinical cancer research 	2005	66
cancer	16105816	1956	Nagai Y	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.	Cancer research	2005	91
cancer	16115926	1956	Psyrri A	Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.	Clinical cancer research 	2005	90
cancer	16145046	1956	Arpino G	Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.	Journal of the National Cancer Institute	2005	100
cancer	16161046	1956	Hanawa M	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.	International journal of cancer	2006	67
cancer	16170173	1956	Philip PA	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.	Journal of clinical oncology 	2005	94
cancer	16204011	1956	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	119
cancer	16230383	1956	Baird K	Gene expression profiling of human sarcomas: insights into sarcoma biology.	Cancer research	2005	85
cancer	16231326	1956	Shigematsu H	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.	International journal of cancer	2006	139
cancer	16261406	1956	Lo HW	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.	Breast cancer research and treatment	2006	63
cancer	16282176	1956	Mellinghoff IK	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.	The New England journal of medicine	2005	399
cancer	16314626	1956	Burtness B	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.	Journal of clinical oncology 	2005	166
cancer	16322287	1956	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	70
cancer	16333527	1956	Hiscox S	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.	Breast cancer research and treatment	2006	64
cancer	16361555	1956	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	161
cancer	16377102	1956	Normanno N	Epidermal growth factor receptor (EGFR) signaling in cancer.	Gene	2006	350
cancer	16397019	1956	Diaz N	Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.	Clinical cancer research 	2006	78
cancer	16424029	1956	Witta SE	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.	Cancer research	2006	137
cancer	16434982	1956	Lo HW	Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.	British journal of cancer	2006	86
cancer	16452222	1956	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	213
cancer	16467097	1956	Riely GJ	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2006	173
cancer	16467544	1956	Bonner JA	Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2006	811
cancer	16533778	1956	Rodríguez-Pinilla SM	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.	Clinical cancer research 	2006	68
cancer	16533793	1956	Tam IY	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.	Clinical cancer research 	2006	112
cancer	16540667	1956	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	61
cancer	16549822	1956	Takeuchi T	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.	Journal of clinical oncology 	2006	64
cancer	16552725	1956	Lo HW	Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.	Journal of cellular biochemistry	2006	84
cancer	16565089	1956	Bourguignon LY	Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells.	The Journal of biological chemistry	2006	74
cancer	16565487	1956	Li YC	Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.	The American journal of pathology	2006	96
cancer	16585219	1956	Creighton CJ	Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.	Cancer research	2006	83
cancer	16730237	1956	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	125
cancer	16740687	1956	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	73
cancer	16757721	1956	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	957
cancer	16763281	1956	Kalyankrishna S	Epidermal growth factor receptor biology in head and neck cancer.	Journal of clinical oncology 	2006	160
cancer	16785471	1956	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	116
cancer	16809731	1956	Philip PA	Phase II study of erlotinib in patients with advanced biliary cancer.	Journal of clinical oncology 	2006	70
cancer	16829981	1956	Citri A	EGF-ERBB signalling: towards the systems level.	Nature reviews. Molecular cell biology	2006	536
cancer	16837691	1956	Zakowski MF	EGFR mutations in small-cell lung cancers in patients who have never smoked.	The New England journal of medicine	2006	65
cancer	16847054	1956	Peng XH	Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.	The Journal of biological chemistry	2006	66
cancer	16890793	1956	Mendelsohn J	Epidermal growth factor receptor targeting in cancer.	Seminars in oncology	2006	150
cancer	16912159	1956	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	96
cancer	16931954	1956	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	68
cancer	16938528	1956	Kim MJ	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.	Human pathology	2006	82
cancer	16980606	1956	Ceppi P	ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.	Annals of oncology 	2006	63
cancer	17020982	1956	Kosaka T	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.	Clinical cancer research 	2006	131
cancer	17030071	1956	Malhi H	Cholangiocarcinoma: modern advances in understanding a deadly old disease.	Journal of hepatology	2006	65
cancer	17047074	1956	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	101
cancer	17047648	1956	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	67
cancer	17050875	1956	Lenz HJ	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Journal of clinical oncology 	2006	90
cancer	17050876	1956	Dragovich T	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.	Journal of clinical oncology 	2006	75
cancer	17075123	1956	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	145
cancer	17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	195
cancer	17115032	1956	Wang SC	Tyrosine phosphorylation controls PCNA function through protein stability.	Nature cell biology	2006	102
cancer	17126425	1956	McCubrey JA	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.	Biochimica et biophysica acta	2007	423
cancer	17146782	1956	Rakha EA	Prognostic markers in triple-negative breast cancer.	Cancer	2007	262
cancer	17189394	1956	Riely GJ	Update on epidermal growth factor receptor mutations in non-small cell lung cancer.	Clinical cancer research 	2006	99
cancer	17189395	1956	Ono M	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.	Clinical cancer research 	2006	79
cancer	17192538	1956	Geyer CE	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	The New England journal of medicine	2006	587
cancer	17206155	1956	Sergina NV	Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.	Nature	2007	280
cancer	17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
cancer	17228019	1956	Jackman DM	Phase II clinical trial of chemotherapy-naive patients &amp;gt; or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2007	82
cancer	17251932	1956	Ventura A	Restoration of p53 function leads to tumour regression in vivo.	Nature	2007	502
cancer	17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
cancer	17290066	1956	Subramanian J	Lung cancer in never smokers: a review.	Journal of clinical oncology 	2007	141
cancer	17290067	1956	Sequist LV	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.	Journal of clinical oncology 	2007	144
cancer	17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
cancer	17308062	1956	Nahta R	Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.	Molecular cancer therapeutics	2007	67
cancer	17314037	1956	Bublil EM	The EGF receptor family: spearheading a merger of signaling and therapeutics.	Current opinion in cell biology	2007	113
cancer	17317677	1956	Hirsch FR	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.	Annals of oncology 	2007	69
cancer	17332301	1956	Kurai J	Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.	Clinical cancer research 	2007	86
cancer	17332364	1956	Mulloy R	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.	Cancer research	2007	62
cancer	17360479	1956	Scott AM	A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.	Proceedings of the National Academy of Sciences of the United States of America	2007	59
cancer	17363584	1956	Benvenuti S	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.	Cancer research	2007	207
cancer	17372238	1956	Yang XR	Differences in risk factors for breast cancer molecular subtypes in a population-based study.	Cancer epidemiology, biomarkers and prevention 	2007	153
cancer	17403429	1956	Smith HO	GPR30: a novel indicator of poor survival for endometrial carcinoma.	American journal of obstetrics and gynecology	2007	74
cancer	17404082	1956	Shaffer DR	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	98
cancer	17409807	1956	Sato M	A translational view of the molecular pathogenesis of lung cancer.	Journal of thoracic oncology 	2007	79
cancer	17440163	1956	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	98
cancer	17452677	1956	Moore MJ	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	Journal of clinical oncology 	2007	820
cancer	17470858	1956	Van Cutsem E	Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.	Journal of clinical oncology 	2007	381
cancer	17473213	1956	Morgillo F	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.	Clinical cancer research 	2007	80
cancer	17473659	1956	Wu YL	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.	Journal of thoracic oncology 	2007	58
cancer	17474783	1956	Huang X	Cancer cells assemble and align gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized surface Raman spectra: a potential cancer diagnostic marker.	Nano letters	2007	58
cancer	17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
cancer	17496923	1956	Roberts PJ	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.	Oncogene	2007	633
cancer	17504988	1956	Massarelli E	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Clinical cancer research 	2007	154
cancer	17538160	1956	Temam S	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.	Journal of clinical oncology 	2007	89
cancer	17538161	1956	Vermorken JB	Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.	Journal of clinical oncology 	2007	158
cancer	17551144	1956	Taguchi F	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.	Journal of the National Cancer Institute	2007	68
cancer	17606725	1956	Wacker B	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.	Clinical cancer research 	2007	84
cancer	17620423	1956	Omuro AM	Lessons learned in the development of targeted therapy for malignant gliomas.	Molecular cancer therapeutics	2007	59
cancer	17623837	1956	Thomas MB	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.	Cancer	2007	69
cancer	17646646	1956	Huang PH	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2007	147
cancer	17663798	1956	Hoadley KA	EGFR associated expression profiles vary with breast tumor subtype.	BMC genomics	2007	101
cancer	17664471	1956	Khambata-Ford S	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.	Journal of clinical oncology 	2007	291
cancer	17664472	1956	Sartore-Bianchi A	Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.	Journal of clinical oncology 	2007	82
cancer	17667926	1956	Hsieh AC	Targeting HER proteins in cancer therapy and the role of the non-target HER3.	British journal of cancer	2007	80
cancer	17670948	1956	Franovic A	Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	68
cancer	17679728	1956	Smith IE	A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.	Journal of clinical oncology 	2007	57
cancer	17699871	1956	Ritter CA	Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.	Clinical cancer research 	2007	166
cancer	17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
cancer	17785546	1956	Molinolo AA	Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.	Clinical cancer research 	2007	70
cancer	17785570	1956	Riely GJ	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.	Clinical cancer research 	2007	93
cancer	17827454	1956	Harari PM	Biology of interactions: antiepidermal growth factor receptor agents.	Journal of clinical oncology 	2007	56
cancer	17888036	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	121
cancer	17894407	1956	De Luca A	The role of the EGFR signaling in tumor microenvironment.	Journal of cellular physiology	2008	89
cancer	17896140	1956	Lieto E	Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.	Annals of surgical oncology	2008	52
cancer	17922188	1956	Tan DS	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.	Breast cancer research and treatment	2008	60
cancer	17947225	1956	Rosell R	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.	Annals of oncology 	2008	60
cancer	17974556	1956	Cappuzzo F	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.	Annals of oncology 	2008	66
cancer	17974918	1956	Okawa T	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.	Genes and development	2007	65
cancer	18003960	1956	Jonker DJ	Cetuximab for the treatment of colorectal cancer.	The New England journal of medicine	2007	366
cancer	18024868	1956	Tabernero J	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2007	63
cancer	18026190	1956	Eskens FA	A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.	British journal of cancer	2008	56
cancer	18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
cancer	18083107	1956	Rikova K	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.	Cell	2007	600
cancer	18087285	1956	Yoshikawa D	Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.	British journal of cancer	2008	79
cancer	18093943	1956	Bean J	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2007	446
cancer	18188694	1956	Cameron D	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.	Breast cancer research and treatment	2008	143
cancer	18211286	1956	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	54
cancer	18236164	1956	Barr S	Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.	Clinical and experimental metastasis	2008	70
cancer	18259690	1956	Wieduwilt MJ	The epidermal growth factor receptor family: biology driving targeted therapeutics.	Cellular and molecular life sciences 	2008	66
cancer	18272912	1956	Tol J	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Annals of oncology 	2008	56
cancer	18281673	1956	Eberhard DA	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.	Journal of clinical oncology 	2008	67
cancer	18283321	1956	Tamura K	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).	British journal of cancer	2008	54
cancer	18297114	1956	Wheeler DL	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.	Oncogene	2008	159
cancer	18303429	1956	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	71
cancer	18304967	1956	Weiss GJ	EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.	Annals of oncology 	2008	74
cancer	18316557	1956	Cheang MC	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.	Clinical cancer research 	2008	299
cancer	18325048	1956	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	61
cancer	18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
cancer	18349398	1956	Miller VA	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.	Journal of clinical oncology 	2008	66
cancer	18362333	1956	Diehn M	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.	Proceedings of the National Academy of Sciences of the United States of America	2008	85
cancer	18375904	1956	Kumar A	Structure and clinical relevance of the epidermal growth factor receptor in human cancer.	Journal of clinical oncology 	2008	58
cancer	18380996	1956	Marur S	Head and neck cancer: changing epidemiology, diagnosis, and treatment.	Mayo Clinic proceedings	2008	84
cancer	18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
cancer	18390971	1956	Sobrero AF	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	168
cancer	18391747	1956	Motoi N	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.	The American journal of surgical pathology	2008	77
cancer	18397279	1956	Kim MA	EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number.	Histopathology	2008	67
cancer	18403491	1956	Sampson JH	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.	Neuro-oncology	2008	54
cancer	18408761	1956	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	267
cancer	18413800	1956	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	58
cancer	18421051	1956	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	97
cancer	18437168	1956	Ladanyi M	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.	Modern pathology 	2008	71
cancer	18452692	1956	Molina JR	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.	Mayo Clinic proceedings	2008	357
cancer	18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
cancer	18486742	1956	Argiris A	Head and neck cancer.	Lancet	2008	285
cancer	18509184	1956	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	56
cancer	18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
cancer	18596266	1956	Maheswaran S	Detection of mutations in EGFR in circulating lung-cancer cells.	The New England journal of medicine	2008	402
cancer	18604200	1956	Kolev V	EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer.	Nature cell biology	2008	67
cancer	18612148	1956	Anders CK	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.	Journal of clinical oncology 	2008	140
cancer	18612151	1956	Hirsch FR	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.	Journal of clinical oncology 	2008	65
cancer	18626007	1956	Zhu CQ	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.	Journal of clinical oncology 	2008	160
cancer	18632642	1956	Lee-Hoeflich ST	A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.	Cancer research	2008	168
cancer	18676761	1956	Wu JY	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.	Clinical cancer research 	2008	71
cancer	18681955	1956	Tamimi RM	Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.	Breast cancer research 	2008	84
cancer	18782861	1956	Tao RH	All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.	Journal of cell science	2008	69
cancer	18794099	1956	Personeni N	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.	Clinical cancer research 	2008	51
cancer	18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
cancer	18821591	1956	Llovet JM	Molecular targeted therapies in hepatocellular carcinoma.	Hepatology	2008	267
cancer	18829483	1956	Lo HW	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.	Clinical cancer research 	2008	65
cancer	18836087	1956	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	80
cancer	18839307	1956	Viale G	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.	Breast cancer research and treatment	2009	51
cancer	18922904	1956	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
cancer	18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
cancer	18936474	1956	Heymach JV	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	56
cancer	18948947	1956	Ding L	Somatic mutations affect key pathways in lung adenocarcinoma.	Nature	2008	865
cancer	18955445	1956	Brown PD	Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.	Journal of clinical oncology 	2008	61
cancer	18955454	1956	Di Leo A	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.	Journal of clinical oncology 	2008	92
cancer	18978815	1956	Pickl M	Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.	Oncogene	2009	84
cancer	18981003	1956	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
cancer	19010870	1956	Bean J	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.	Clinical cancer research 	2008	77
cancer	19010912	1956	Pratilas CA	Genetic predictors of MEK dependence in non-small cell lung cancer.	Cancer research	2008	83
cancer	19010923	1956	Yano S	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer research	2008	169
cancer	19027483	1956	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	258
cancer	19047149	1956	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	65
cancer	19058255	1956	Xia W	Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.	Molecular carcinogenesis	2009	67
cancer	19060928	1956	Scaltriti M	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.	Oncogene	2009	103
cancer	19073608	1956	Webster RJ	Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.	The Journal of biological chemistry	2009	138
cancer	19075262	1956	Prados MD	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.	Journal of clinical oncology 	2009	88
cancer	19088172	1956	Gow CH	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.	Annals of oncology 	2009	47
cancer	19089838	1956	Yang L	Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.	Small	2009	87
cancer	19091906	1956	Aerts HJ	Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.	Journal of nuclear medicine 	2009	53
cancer	19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
cancer	19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
cancer	19114685	1956	Hecht JR	A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.	Journal of clinical oncology 	2009	180
cancer	19117999	1956	Huang F	The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.	Cancer research	2009	63
cancer	19118495	1956	Sahin O	Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.	BMC systems biology	2009	52
cancer	19147502	1956	Griffero F	Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.	The Journal of biological chemistry	2009	49
cancer	19150933	1956	Corkery B	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.	Annals of oncology 	2009	66
cancer	19169683	1956	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	59
cancer	19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
cancer	19176518	1956	Fan QW	EGFR signals to mTOR through PKC and independently of Akt in glioma.	Science signaling	2009	60
cancer	19188670	1956	Allegra CJ	American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.	Journal of clinical oncology 	2009	311
cancer	19201650	1956	Cohen EE	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.	The Lancet. Oncology	2009	52
cancer	19204207	1956	van den Bent MJ	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.	Journal of clinical oncology 	2009	110
cancer	19217204	1956	Montagut C	Targeting the RAF-MEK-ERK pathway in cancer therapy.	Cancer letters	2009	108
cancer	19224850	1956	Inoue A	First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.	Journal of clinical oncology 	2009	84
cancer	19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
cancer	19234131	1956	Al-Nedawi K	Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2009	141
cancer	19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
cancer	19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
cancer	19255323	1956	Cappuzzo F	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.	Journal of clinical oncology 	2009	114
cancer	19276259	1956	Yung TK	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.	Clinical cancer research 	2009	99
cancer	19276389	1956	Narayan M	Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.	Cancer research	2009	69
cancer	19276677	1956	Wheeler DL	Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.	Cancer biology and therapy	2009	55
cancer	19289630	1956	Stewart JS	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck corrected.	Journal of clinical oncology 	2009	57
cancer	19296866	1956	Johnson LN	Protein kinase inhibitors: contributions from structure to clinical compounds.	Quarterly reviews of biophysics	2009	58
cancer	19319529	1956	López-Albaitero A	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.	Cancer immunology, immunotherapy 	2009	54
cancer	19332730	1956	Natale RB	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.	Journal of clinical oncology 	2009	51
cancer	19346299	1956	Ross JS	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.	The oncologist	2009	199
cancer	19351754	1956	Kuang Y	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.	Clinical cancer research 	2009	65
cancer	19366827	1956	Yu J	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.	Clinical cancer research 	2009	54
cancer	19410716	1956	Pirker R	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.	Lancet	2009	294
cancer	19412429	1956	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	48
cancer	19414683	1956	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	84
cancer	19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
cancer	19421880	1956	Dembinski JL	Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.	Clinical and experimental metastasis	2009	60
cancer	19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
cancer	19480968	1956	Kuremsky JG	Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.	International journal of radiation oncology, biology, physics	2009	56
cancer	19483740	1956	Linardou H	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.	Nature reviews. Clinical oncology	2009	57
cancer	19490536	1956	Stuffers S	Multivesicular endosome biogenesis in the absence of ESCRTs.	Traffic	2009	58
cancer	19536107	1956	Baselga J	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.	Nature reviews. Cancer	2009	312
cancer	19536109	1956	Walther A	Genetic prognostic and predictive markers in colorectal cancer.	Nature reviews. Cancer	2009	170
cancer	19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
cancer	19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
cancer	19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
cancer	19597023	1956	Mandrekar SJ	Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.	Journal of clinical oncology 	2009	74
cancer	19625624	1956	Guo D	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2009	81
cancer	19632948	1956	Nguyen KS	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.	Clinical lung cancer	2009	108
cancer	19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
cancer	19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
cancer	19671762	1956	Liu TJ	NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.	Molecular cancer therapeutics	2009	89
cancer	19671843	1956	Jackman DM	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clinical cancer research 	2009	111
cancer	19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	163
cancer	19680294	1956	Hirsch FR	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.	Oncogene	2009	56
cancer	19689244	1956	Hartmann JT	Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.	Current drug metabolism	2009	56
cancer	19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
cancer	19692680	1956	Mok TS	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.	The New England journal of medicine	2009	1545
cancer	19692684	1956	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	452
cancer	19706799	1956	Desbois-Mouthon C	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.	Clinical cancer research 	2009	57
cancer	19720911	1956	Millar EK	Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.	Journal of clinical oncology 	2009	60
cancer	19723643	1956	Krishnaswamy S	Ethnic differences and functional analysis of MET mutations in lung cancer.	Clinical cancer research 	2009	55
cancer	19738203	1956	Huang PH	Oncogenic EGFR signaling networks in glioma.	Science signaling	2009	92
cancer	19775602	1956	Dawson SJ	Triple negative breast cancers: clinical and prognostic implications.	European journal of cancer	2009	55
cancer	19786658	1956	Johnston S	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Journal of clinical oncology 	2009	191
cancer	19787002	1956	Kim LC	Src kinases as therapeutic targets for cancer.	Nature reviews. Clinical oncology	2009	214
cancer	19806185	1956	Sartore-Bianchi A	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.	PloS one	2009	85
cancer	19825799	1956	Sampson JH	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.	Molecular cancer therapeutics	2009	75
cancer	19840943	1956	Demory ML	Epidermal growth factor receptor translocation to the mitochondria: regulation and effect.	The Journal of biological chemistry	2009	48
cancer	19852961	1956	Goetz M	In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor.	Gastroenterology	2010	59
cancer	19861462	1956	Wang SC	Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.	Clinical cancer research 	2009	63
cancer	19884552	1956	Spector NL	Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2009	110
cancer	19884556	1956	Laurent-Puig P	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.	Journal of clinical oncology 	2009	189
cancer	19914732	1956	Dempke WC	Targeted therapies for non-small cell lung cancer.	Lung cancer	2010	44
cancer	19917871	1956	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	139
cancer	19920198	1956	Gravendeel LA	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.	Cancer research	2009	128
cancer	19934333	1956	Scheuer W	Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.	Cancer research	2009	118
cancer	19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
cancer	19949011	1956	Jackman D	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Journal of clinical oncology 	2010	156
cancer	19949019	1956	Hanrahan EO	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2010	52
cancer	19960228	1956	Peereboom DM	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.	Journal of neuro-oncology	2010	57
cancer	20012924	1956	McConkey DJ	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.	Cancer metastasis reviews	2009	81
cancer	20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
cancer	20027191	1956	Esteva FJ	Molecular predictors of response to trastuzumab and lapatinib in breast cancer.	Nature reviews. Clinical oncology	2010	48
cancer	20028749	1956	Dahabreh IJ	Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2010	44
cancer	20038723	1956	Douillard JY	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.	Journal of clinical oncology 	2010	141
cancer	20048743	1956	Zhou X	Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.	Laboratory investigation; a journal of technical methods and pathology	2010	94
cancer	20049729	1956	Watt FM	Epidermal stem cell diversity and quiescence.	EMBO molecular medicine	2009	69
cancer	20064507	1956	Kruser TJ	Mechanisms of resistance to HER family targeting antibodies.	Experimental cell research	2010	50
cancer	20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
cancer	20082448	1956	Rimawi MF	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.	Cancer	2010	45
cancer	20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
cancer	20100961	1956	Bardelli A	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.	Journal of clinical oncology 	2010	160
cancer	20100966	1956	Lynch TJ	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.	Journal of clinical oncology 	2010	103
cancer	20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
cancer	20108024	1956	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	44
cancer	20113523	1956	Ren Y	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.	BMC cancer	2010	47
cancer	20124471	1956	McDermott U	Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.	Cancer research	2010	51
cancer	20129249	1956	Turke AB	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.	Cancer cell	2010	279
cancer	20130423	1956	Lurje G	EGFR signaling and drug discovery.	Oncology	2009	103
cancer	20142592	1956	Haura EB	Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	57
cancer	20142600	1956	Lacouture ME	Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	59
cancer	20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
cancer	20150372	1956	Raizer JJ	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.	Neuro-oncology	2010	56
cancer	20179223	1956	Campbell MR	HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.	Clinical cancer research 	2010	55
cancer	20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
cancer	20194857	1956	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	212
cancer	20332324	1956	Johnston SR	New strategies in estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	61
cancer	20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
cancer	20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
cancer	20431034	1956	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	105
cancer	20479403	1956	Sequist LV	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	96
cancer	20493771	1956	Cappuzzo F	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.	The Lancet. Oncology	2010	278
cancer	20501798	1956	O'Brien NA	Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.	Molecular cancer therapeutics	2010	83
cancer	20508278	1956	Ghosh N	COX-2 as a target for cancer chemotherapy.	Pharmacological reports 	2010	54
cancer	20515495	1956	Krakstad C	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Molecular cancer	2010	65
cancer	20520800	1956	Blows FM	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.	PLoS medicine	2010	185
cancer	20530271	1956	Lubner SJ	Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.	Journal of clinical oncology 	2010	55
cancer	20530283	1956	Alvarez RH	Emerging targeted therapies for breast cancer.	Journal of clinical oncology 	2010	41
cancer	20551942	1956	Wheeler DL	Understanding resistance to EGFR inhibitors-impact on future treatment strategies.	Nature reviews. Clinical oncology	2010	173
cancer	20551945	1956	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	61
cancer	20562913	1956	Gan Y	Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.	Oncogene	2010	73
cancer	20570559	1956	Herbst RS	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	2010	99
cancer	20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	979
cancer	20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
cancer	20621056	1956	Curtis SJ	Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.	Cell stem cell	2010	50
cancer	20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
cancer	20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
cancer	20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
cancer	20716591	1956	Sathornsumetee S	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.	Neuro-oncology	2010	48
cancer	20736298	1956	Cameron D	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.	The oncologist	2010	49
cancer	20736484	1956	Moritz A	Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases.	Science signaling	2010	100
cancer	20798686	1956	Li QQ	Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.	Cell death and differentiation	2011	40
cancer	20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
cancer	20838621	1956	Punnoose EA	Molecular biomarker analyses using circulating tumor cells.	PloS one	2010	78
cancer	20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
cancer	20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
cancer	20858720	1956	Mazzoleni S	Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.	Cancer research	2010	65
cancer	20861192	1956	Hochgräfe F	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.	Cancer research	2010	56
cancer	20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
cancer	20871269	1956	Pirker R	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.	Journal of thoracic oncology 	2010	57
cancer	20874002	1956	Katakowski M	MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma.	Cancer investigation	2010	47
cancer	20887192	1956	da Cunha Santos G	EGFR mutations and lung cancer.	Annual review of pathology	2011	65
cancer	20887199	1956	Osborne CK	Mechanisms of endocrine resistance in breast cancer.	Annual review of medicine	2011	214
cancer	20921459	1956	Sampson JH	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	184
cancer	20921461	1956	Roberts PJ	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	Journal of clinical oncology 	2010	77
cancer	20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
cancer	20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	342
cancer	20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
cancer	20943624	1956	Vermorken JB	Optimal treatment for recurrent/metastatic head and neck cancer.	Annals of oncology 	2010	51
cancer	20966921	1956	Pao W	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.	Nature reviews. Cancer	2010	237
cancer	21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
cancer	21048039	1956	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	54
cancer	21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
cancer	21062933	1956	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	47
cancer	21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
cancer	21135146	1956	Oxnard GR	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.	Clinical cancer research 	2011	102
cancer	21160078	1956	Weiss J	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.	Science translational medicine	2010	191
cancer	21160525	1956	Leemans CR	The molecular biology of head and neck cancer.	Nature reviews. Cancer	2011	466
cancer	21161370	1956	Pal SK	Triple negative breast cancer: unmet medical needs.	Breast cancer research and treatment	2011	74
cancer	21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
cancer	21165163	1956	Zhang Z	EGFR-mutated lung cancer: a paradigm of molecular oncology.	Oncotarget	2010	53
cancer	21168239	1956	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	39
cancer	21200037	1956	Dahabreh IJ	Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.	Annals of internal medicine	2011	47
cancer	21220471	1956	Jänne PA	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.	Clinical cancer research 	2011	39
cancer	21220474	1956	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	37
cancer	21220480	1956	Osborne CK	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.	Clinical cancer research 	2011	52
cancer	21233402	1956	Rosell R	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.	Clinical cancer research 	2011	78
cancer	21252999	1956	Avraham R	Feedback regulation of EGFR signalling: decision making by early and delayed loops.	Nature reviews. Molecular cell biology	2011	180
cancer	21253578	1956	Gu TL	Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.	PloS one	2011	89
cancer	21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
cancer	21258415	1956	Normant E	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene	2011	46
cancer	21266349	1956	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	65
cancer	21266357	1956	Qi J	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	Cancer research	2011	49
cancer	21273060	1956	Krumbach R	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.	European journal of cancer	2011	39
cancer	21277552	1956	Pao W	New driver mutations in non-small-cell lung cancer.	The Lancet. Oncology	2011	244
cancer	21282537	1956	de Boer RH	Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2011	61
cancer	21282542	1956	Natale RB	Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	65
cancer	21289483	1956	Cho WC	MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1.	RNA biology	2011	53
cancer	21293176	1956	Brand TM	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.	Cancer biology and therapy	2011	40
cancer	21303969	1956	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	87
cancer	21324925	1956	Ghosh R	Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.	Cancer research	2011	50
cancer	21377930	1956	Machiels JP	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2011	36
cancer	21407195	1956	Maretzky T	Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.	Nature communications	2011	38
cancer	21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
cancer	21412767	1956	Zhang Y	Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway.	Journal of cellular physiology	2012	34
cancer	21422426	1956	Zander T	Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using (18)Ffluorodeoxyglucose and (18)Ffluorothymidine positron emission tomography.	Journal of clinical oncology 	2011	37
cancer	21430269	1956	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	619
cancer	21430781	1956	Bivona TG	FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.	Nature	2011	99
cancer	21468131	1956	Okines A	Targeting the human EGFR family in esophagogastric cancer.	Nature reviews. Clinical oncology	2011	43
cancer	21471286	1956	Hegi ME	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.	Molecular cancer therapeutics	2011	35
cancer	21482987	1956	D'Angelo SP	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.	Journal of clinical oncology 	2011	59
cancer	21482992	1956	Keedy VL	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.	Journal of clinical oncology 	2011	117
cancer	21483012	1956	Paik PK	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.	Journal of clinical oncology 	2011	115
cancer	21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
cancer	21531810	1956	Wu JY	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.	Clinical cancer research 	2011	85
cancer	21555682	1956	Blumenschein GR Jr	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.	Journal of clinical oncology 	2011	46
cancer	21576636	1956	Spigel DR	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	40
cancer	21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
cancer	21630130	1956	Lacouture ME	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.	Supportive care in cancer 	2011	37
cancer	21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
cancer	21646616	1956	Price TJ	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.	Journal of clinical oncology 	2011	58
cancer	21653320	1956	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	95
cancer	21655094	1956	Han W	EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.	PloS one	2011	61
cancer	21687663	1956	Li N	Inhibition of cell proliferation by an anti-EGFR aptamer.	PloS one	2011	41
cancer	21690342	1956	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	30
cancer	21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
cancer	21730270	1956	Yatabe Y	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.	Journal of clinical oncology 	2011	46
cancer	21734175	1956	Chmielecki J	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.	Science translational medicine	2011	156
cancer	21764376	1956	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	79
cancer	21768463	1956	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	120
cancer	21775534	1956	Oxnard GR	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.	Clinical cancer research 	2011	83
cancer	21782507	1956	O'Byrne KJ	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2011	55
cancer	21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
cancer	21788562	1956	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	61
cancer	21791641	1956	Sasaki T	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.	Cancer research	2011	157
cancer	21830014	1956	Tamimi RM	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	47
cancer	21849857	1956	Janku F	Novel therapeutic targets in non-small cell lung cancer.	Journal of thoracic oncology 	2011	38
cancer	21856766	1956	Chaft JE	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.	Clinical cancer research 	2011	90
cancer	21862980	1956	Mok TS	Personalized medicine in lung cancer: what we need to know.	Nature reviews. Clinical oncology	2011	40
cancer	21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
cancer	21886163	1956	Breitbach CJ	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.	Nature	2011	138
cancer	21893191	1956	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	62
cancer	21900593	1956	Yonesaka K	Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.	Science translational medicine	2011	134
cancer	21900837	1956	Goto K	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Journal of thoracic oncology 	2012	51
cancer	21909139	1956	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	36
cancer	21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
cancer	21926387	1956	Travis WD	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.	Proceedings of the American Thoracic Society	2011	71
cancer	21969500	1956	Brugger W	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	68
cancer	21976538	1956	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	75
cancer	21990576	1956	Terwisscha van Scheltinga AG	Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.	Journal of nuclear medicine 	2011	51
cancer	22003071	1956	LoRusso PM	Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.	Clinical cancer research 	2011	65
cancer	22025148	1956	Lai A	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.	Journal of clinical oncology 	2011	91
cancer	22025157	1956	Ramalingam SS	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.	Journal of clinical oncology 	2011	59
cancer	22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
cancer	22052230	1956	Yano S	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.	Journal of thoracic oncology 	2011	47
cancer	22054879	1956	Travis WD	Pathology of lung cancer.	Clinics in chest medicine	2011	59
cancer	22056021	1956	Pirker R	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2012	132
cancer	22065080	1956	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	44
cancer	22080568	1956	Okayama H	Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.	Cancer research	2012	124
cancer	22112968	1956	He X	Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.	Annals of oncology 	2012	49
cancer	22119437	1956	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	35
cancer	22127113	1956	Brand TM	The nuclear epidermal growth factor receptor signaling network and its role in cancer.	Discovery medicine	2011	51
cancer	22135231	1956	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	55
cancer	22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
cancer	22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.	Oncogene	2012	52
cancer	22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
cancer	22144946	1956	Karar J	PI3K/AKT/mTOR Pathway in Angiogenesis.	Frontiers in molecular neuroscience	2011	107
cancer	22162641	1956	Ou SH	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.	Drug design, development and therapy	2011	37
cancer	22173704	1956	Krebs MG	Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.	Journal of thoracic oncology 	2012	101
cancer	22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
cancer	22186794	1956	Parato KA	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.	Molecular therapy 	2012	47
cancer	22189713	1956	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	48
cancer	22191652	1956	Zhang Y	PET tracers based on Zirconium-89.	Current radiopharmaceuticals	2011	40
cancer	22194472	1956	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	122
cancer	22207554	1956	Park S	High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.	Histology and histopathology	2012	35
cancer	22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
cancer	22215752	1956	Su KY	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	111
cancer	22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
cancer	22228822	1956	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	34
cancer	22235099	1956	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	213
cancer	22237264	1956	Sun PL	High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.	Journal of thoracic oncology 	2012	34
cancer	22239438	1956	Seshacharyulu P	Targeting the EGFR signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	73
cancer	22261334	1956	Han W	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.	Cancer letters	2012	64
cancer	22270724	1956	Montagut C	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.	Nature medicine	2012	100
cancer	22277784	1956	Katayama R	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.	Science translational medicine	2012	268
cancer	22281684	1956	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	392
cancer	22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
cancer	22282308	1956	Cheng L	Molecular pathology of lung cancer: key to personalized medicine.	Modern pathology 	2012	41
cancer	22285168	1956	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	876
cancer	22305568	1956	Spike BT	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.	Cell stem cell	2012	56
cancer	22315472	1956	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	127
cancer	22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
cancer	22370318	1956	Lee JS	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).	Journal of clinical oncology 	2012	70
cancer	22407829	1956	Perez-Moreno P	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.	Clinical cancer research 	2012	48
cancer	22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
cancer	22418026	1956	Oliveira S	Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.	Molecular imaging	2012	34
cancer	22418700	1956	Lin NU	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.	Breast cancer research and treatment	2012	44
cancer	22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
cancer	22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
cancer	22452803	1956	Fokas E	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.	Radiation oncology	2012	30
cancer	22452895	1956	Yang JC	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.	The Lancet. Oncology	2012	76
cancer	22452896	1956	Miller VA	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.	The Lancet. Oncology	2012	210
cancer	22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
cancer	22464348	1956	Couraud S	Lung cancer in never smokers--a review.	European journal of cancer	2012	51
cancer	22492982	1956	Punnoose EA	Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.	Clinical cancer research 	2012	75
cancer	22505743	1956	Navani N	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.	American journal of respiratory and critical care medicine	2012	53
cancer	22508830	1956	Witta SE	Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.	Journal of clinical oncology 	2012	50
cancer	22520625	1956	Wang YN	Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family.	Cell and bioscience	2012	32
cancer	22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
cancer	22541616	1956	Saintigny P	Recent advances in non-small cell lung cancer biology and clinical management.	Discovery medicine	2012	33
cancer	22547605	1956	Jänne PA	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.	Journal of clinical oncology 	2012	75
cancer	22552284	1956	Turke AB	MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.	Cancer research	2012	72
cancer	22564989	1956	Scagliotti GV	Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.	Journal of clinical oncology 	2012	50
cancer	22579283	1956	Lee MJ	Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.	Cell	2012	180
cancer	22588883	1956	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	73
cancer	22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
cancer	22591372	1956	Gorges TM	Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.	BMC cancer	2012	110
cancer	22605616	1956	Goldman JW	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.	Cancer	2012	35
cancer	22611028	1956	Roselli M	Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.	Clinical cancer research 	2012	36
cancer	22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	209
cancer	22658319	1956	Hurvitz SA	Current approaches and future directions in the treatment of HER2-positive breast cancer.	Cancer treatment reviews	2013	29
cancer	22673630	1956	Chen ZY	EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.	The oncologist	2012	36
cancer	22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
cancer	22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	333
cancer	22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
cancer	22751098	1956	Zhang Z	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nature genetics	2012	263
cancer	22753918	1956	Ramalingam SS	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2012	63
cancer	22764208	1956	Issadore D	Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector.	Science translational medicine	2012	55
cancer	22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
cancer	22773810	1956	Ohashi K	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.	Proceedings of the National Academy of Sciences of the United States of America	2012	121
cancer	22778317	1956	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	54
cancer	22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
cancer	22785351	1956	Yarden Y	The ERBB network: at last, cancer therapy meets systems biology.	Nature reviews. Cancer	2012	143
cancer	22797485	1956	Zhao X	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.	Respiration; international review of thoracic diseases	2013	30
cancer	22806307	1956	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	34
cancer	22810899	1956	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	32
cancer	22826274	1956	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	60
cancer	22843788	1956	Tanizaki J	Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.	Clinical cancer research 	2012	46
cancer	22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
cancer	22864381	1956	Komurov K	The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.	Molecular systems biology	2012	32
cancer	22888144	1956	Solca F	Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.	The Journal of pharmacology and experimental therapeutics	2012	95
cancer	22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
cancer	22898037	1956	Argiris A	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.	Annals of oncology 	2013	34
cancer	22898678	1956	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	56
cancer	22949147	1956	Van Cutsem E	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.	Journal of clinical oncology 	2012	183
cancer	22956860	1956	Creighton CJ	The molecular profile of luminal B breast cancer.	Biologics 	2012	45
cancer	22961667	1956	Ercan D	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.	Cancer discovery	2012	77
cancer	22964225	1956	Johnson H	Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.	Molecular and cellular proteomics 	2012	30
cancer	22967997	1956	Inoue A	Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).	Annals of oncology 	2013	73
cancer	22977193	1956	Terashima M	Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.	Clinical cancer research 	2012	59
cancer	23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
cancer	23012302	1956	André F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	58
cancer	23014527	1956	Dogan S	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.	Clinical cancer research 	2012	74
cancer	23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
cancer	23045285	1956	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	35
cancer	23052255	1956	Suehara Y	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.	Clinical cancer research 	2012	35
cancer	23070115	1956	Uchida H	Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.	Molecular therapy 	2013	26
cancer	23073759	1956	Masuda H	Role of epidermal growth factor receptor in breast cancer.	Breast cancer research and treatment	2012	81
cancer	23079155	1956	Yang JJ	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.	Lung cancer	2013	33
cancer	23084121	1956	Nielsen DL	Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.	Breast	2013	26
cancer	23103856	1956	Young A	Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.	Cancer discovery	2013	48
cancer	23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
cancer	23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	36
cancer	23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
cancer	23149820	1956	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	49
cancer	23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
cancer	23154553	1956	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	36
cancer	23172311	1956	Huang S	Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.	Cancer research	2013	34
cancer	23172555	1956	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	49
cancer	23221996	1956	Ocana A	HER3 overexpression and survival in solid tumors: a meta-analysis.	Journal of the National Cancer Institute	2013	48
cancer	23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
cancer	23242438	1956	Yoshizawa A	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.	Journal of thoracic oncology 	2013	67
cancer	23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	99
cancer	23265711	1956	Licitra L	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.	European journal of cancer	2013	27
cancer	23280481	1956	Chen CL	Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.	The Prostate	2013	44
cancer	23319610	1956	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
cancer	23332287	1956	Gadgeel SM	Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.	Clinical lung cancer	2013	29
cancer	23333074	1956	Zaiss DM	Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.	Immunity	2013	49
cancer	23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
cancer	23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
cancer	23344264	1956	Yeh P	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.	Clinical cancer research 	2013	35
cancer	23358903	1956	Bayraktar S	Molecularly targeted therapies for metastatic triple-negative breast cancer.	Breast cancer research and treatment	2013	31
cancer	23361103	1956	Gonzalez de Castro D	Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.	Clinical pharmacology and therapeutics	2013	47
cancer	23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
cancer	23370315	1956	Hirsch FR	Epidermal growth factor receptor inhibition in lung cancer: status 2012.	Journal of thoracic oncology 	2013	26
cancer	23375249	1956	Heinemann V	Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.	Cancer treatment reviews	2013	28
cancer	23383079	1956	Liu HB	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.	PloS one	2013	25
cancer	23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
cancer	23401433	1956	Li T	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.	Journal of clinical oncology 	2013	86
cancer	23401440	1956	Roberts PJ	KRAS mutation: should we test for it, and does it matter?	Journal of clinical oncology 	2013	54
cancer	23401443	1956	Travis WD	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.	Journal of clinical oncology 	2013	68
cancer	23401448	1956	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	27
cancer	23401451	1956	Ohashi K	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.	Journal of clinical oncology 	2013	103
cancer	23401452	1956	Laurie SA	Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.	Journal of clinical oncology 	2013	29
cancer	23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
cancer	23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
cancer	23542173	1956	Yamaguchi H	Signaling cross-talk in the resistance to HER family receptor targeted therapy.	Oncogene	2014	27
cancer	23547110	1956	Drier Y	Pathway-based personalized analysis of cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	39
cancer	23551194	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Archives of pathology and laboratory medicine	2013	68
cancer	23552377	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	124
cancer	23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
cancer	23555746	1956	Luca AC	Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines.	PloS one	2013	36
cancer	23562183	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	60
cancer	23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
cancer	23576557	1956	Keysar SB	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.	Cancer research	2013	26
cancer	23584089	1956	Sadanandam A	A colorectal cancer classification system that associates cellular phenotype and responses to therapy.	Nature medicine	2013	186
cancer	23584090	1956	De Sousa E Melo F	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.	Nature medicine	2013	132
cancer	23589544	1956	Buettner R	Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.	Journal of clinical oncology 	2013	33
cancer	23594426	1956	Lee CK	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.	Journal of the National Cancer Institute	2013	98
cancer	23607916	1956	Keysar SB	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.	Molecular oncology	2013	32
cancer	23633480	1956	Chettouh H	Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.	Cancer research	2013	32
cancer	23636329	1956	Shen J	EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.	Nature	2013	100
cancer	23645635	1956	Rizvi I	Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.	Proceedings of the National Academy of Sciences of the United States of America	2013	32
cancer	23653350	1956	Balanis N	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.	The Journal of biological chemistry	2013	29
cancer	23676460	1956	Banck MS	The genomic landscape of small intestine neuroendocrine tumors.	The Journal of clinical investigation	2013	36
cancer	23707073	1956	Babic I	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.	Cell metabolism	2013	30
cancer	23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
cancer	23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
cancer	23729478	1956	Bardelli A	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.	Cancer discovery	2013	126
cancer	23733761	1956	Baselga J	Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.	Journal of clinical oncology 	2013	66
cancer	23768755	1956	Roengvoraphoj M	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.	Cancer treatment reviews	2013	25
cancer	23777544	1956	Gan HK	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.	The FEBS journal	2013	46
cancer	23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
cancer	23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
cancer	23816963	1956	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	63
cancer	23816967	1956	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	49
cancer	23829935	1956	Remon J	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.	Cancer treatment reviews	2014	22
cancer	23830194	1956	Brand TM	Nuclear EGFR as a molecular target in cancer.	Radiotherapy and oncology 	2013	38
cancer	23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	34
cancer	23852704	1956	Duffy MJ	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.	International journal of cancer	2014	26
cancer	23872583	1956	Kanda R	Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.	Cancer research	2013	28
cancer	23883922	1956	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	116
cancer	23888061	1956	Liu X	The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.	Journal of clinical pathology	2013	29
cancer	23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
cancer	23894143	1956	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	32
cancer	23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
cancer	23948351	1956	Shi Y	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.	The Lancet. Oncology	2013	73
cancer	23953842	1956	Yewale C	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.	Biomaterials	2013	44
cancer	23972815	1956	Rosell R	Genetics and biomarkers in personalisation of lung cancer treatment.	Lancet	2013	60
cancer	23980091	1956	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	40
cancer	24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
cancer	24026012	1956	Giles KM	Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.	Molecular cancer therapeutics	2013	29
cancer	24034250	1956	Wei Y	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.	Cell	2013	104
cancer	24044505	1956	Xia W	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.	Breast cancer research 	2013	31
cancer	24065731	1956	Walter AO	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.	Cancer discovery	2013	122
cancer	24072220	1956	Goldberg SB	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.	The oncologist	2013	37
cancer	24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
cancer	24101047	1956	Gainor JF	Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.	Journal of clinical oncology 	2013	67
cancer	24101053	1956	Spigel DR	Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2013	93
cancer	24105277	1956	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	38
cancer	24122263	1956	Cummings MC	Metastatic progression of breast cancer: insights from 50 years of autopsies.	The Journal of pathology	2014	25
cancer	24122793	1956	Troiani T	Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.	Clinical cancer research 	2013	36
cancer	24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
cancer	24165158	1956	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	29
cancer	24174329	1956	Clinical Lung Cancer Genome Project (CLCGP).	A genomics-based classification of human lung tumors.	Science translational medicine	2013	74
cancer	24199682	1956	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	23
cancer	24199791	1956	Ahmad A	Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.	Journal of hematology and oncology	2013	29
cancer	24202392	1956	Chong CR	The quest to overcome resistance to EGFR-targeted therapies in cancer.	Nature medicine	2013	168
cancer	24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
cancer	24248375	1956	Drake JM	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.	Proceedings of the National Academy of Sciences of the United States of America	2013	28
cancer	24263064	1956	Douillard JY	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.	British journal of cancer	2014	33
cancer	24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
cancer	24285021	1956	Beau-Faller M	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.	Annals of oncology 	2014	26
cancer	24310612	1956	Nathanson DA	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.	Science	2014	70
cancer	24335959	1956	Huang WC	miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis.	Cancer research	2014	31
cancer	24353160	1956	Yasuda H	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.	Science translational medicine	2013	45
cancer	24366937	1956	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	23
cancer	24378644	1956	Siegelin MD	Epidermal growth factor receptor mutations in lung adenocarcinoma.	Laboratory investigation; a journal of technical methods and pathology	2014	40
cancer	24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
cancer	24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
cancer	24406864	1956	Park HS	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.	Modern pathology 	2014	33
cancer	24419411	1956	Shi Y	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).	Journal of thoracic oncology 	2014	113
cancer	24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
cancer	24429876	1956	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	111
cancer	24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
cancer	24443522	1956	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	29
cancer	24448239	1956	Luraghi P	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.	Cancer research	2014	23
cancer	24458568	1956	Suda K	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	International journal of cancer	2014	22
cancer	24470557	1956	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	23
cancer	24478319	1956	Yu HA	Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.	Annals of oncology 	2014	23
cancer	24501009	1956	Reckamp KL	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.	Cancer	2014	23
cancer	24508104	1956	André F	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).	The Lancet. Oncology	2014	55
cancer	24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
cancer	24533047	1956	Liang W	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.	PloS one	2014	21
cancer	24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
cancer	24553385	1956	Bettegowda C	Detection of circulating tumor DNA in early- and late-stage human malignancies.	Science translational medicine	2014	385
cancer	24553387	1956	Misale S	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.	Science translational medicine	2014	58
cancer	24621885	1956	Zhang Y	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.	PloS one	2014	21
cancer	24626858	1956	Nagatsuma AK	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.	Gastric cancer 	2015	24
cancer	24632568	1956	Gasparini P	microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.	Oncotarget	2014	46
cancer	24644001	1956	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	43
cancer	24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
cancer	24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
cancer	24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	139
cancer	24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
cancer	24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
cancer	24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
cancer	24687921	1956	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	26
cancer	24715074	1956	Lee JK	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.	JAMA	2014	27
cancer	24739896	1956	Price TJ	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.	The Lancet. Oncology	2014	49
cancer	24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
cancer	24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
cancer	24773774	1956	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	25
cancer	24816687	1956	Zhou X	MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.	PloS one	2014	24
cancer	24831979	1956	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	39
cancer	24841974	1956	Kawaguchi T	Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).	Journal of clinical oncology 	2014	53
cancer	24846037	1956	Kris MG	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.	JAMA	2014	182
cancer	24857062	1956	Abrams J	National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	32
cancer	24857124	1956	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	23
cancer	24863259	1956	Fumarola C	Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.	Biochemical pharmacology	2014	42
cancer	24867380	1956	Liu S	Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.	Cancer treatment reviews	2014	28
cancer	24868098	1956	Khozin S	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	The oncologist	2014	20
cancer	24886126	1956	Ma J	Targeting of erbB3 receptor to overcome resistance in cancer treatment.	Molecular cancer	2014	28
cancer	24893891	1956	Cross DA	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.	Cancer discovery	2014	170
cancer	24895374	1956	Rohan TE	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.	Journal of the National Cancer Institute	2014	33
cancer	24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
cancer	24919575	1956	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	20
cancer	24928832	1956	Seiwert TY	A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.	Annals of oncology 	2014	21
cancer	24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
cancer	24981256	1956	Camidge DR	Acquired resistance to TKIs in solid tumours: learning from lung cancer.	Nature reviews. Clinical oncology	2014	107
cancer	24986882	1956	Grusch M	Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.	The EMBO journal	2014	29
cancer	25009014	1956	Azuma K	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.	Annals of oncology 	2014	66
cancer	25009231	1956	Rebouissou S	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.	Science translational medicine	2014	33
cancer	25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
cancer	25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
cancer	25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
cancer	25074459	1956	Janjigian YY	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.	Cancer discovery	2014	69
cancer	25079552	1956	Cancer Genome Atlas Research Network.	Comprehensive molecular profiling of lung adenocarcinoma.	Nature	2014	567
cancer	25080476	1956	Müller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
cancer	25091798	1956	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	30
cancer	25103305	1956	Sorensen BS	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.	Cancer	2014	32
cancer	25115304	1956	Sorich MJ	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.	Annals of oncology 	2015	68
cancer	25122430	1956	Douillard JY	Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.	Journal of thoracic oncology 	2014	62
cancer	25125659	1956	Wilson C	AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.	Cancer research	2014	22
cancer	25136066	1956	Brand TM	AXL mediates resistance to cetuximab therapy.	Cancer research	2014	27
cancer	25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
cancer	25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
cancer	25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
cancer	25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
cancer	25185971	1956	Satoh T	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.	Gastric cancer 	2015	20
cancer	25193862	1956	Wilson C	Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.	Oncotarget	2014	28
cancer	25222496	1956	Zhang Y	Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.	PloS one	2014	27
cancer	25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
cancer	25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
cancer	25271963	1956	Finlay MR	Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.	Journal of medicinal chemistry	2014	27
cancer	25293556	1956	Misale S	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.	Cancer discovery	2014	48
cancer	25311215	1956	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	42
cancer	25339418	1956	Qiu M	Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.	Cancer epidemiology, biomarkers and prevention 	2015	30
cancer	25345567	1956	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	29
cancer	25349291	1956	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	23
cancer	25349974	1956	D'Incecco A	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	69
cancer	25394791	1956	Crystal AS	Patient-derived models of acquired resistance can identify effective drug combinations for cancer.	Science	2014	120
cancer	25405368	1956	Chiyomaru T	Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer.	International journal of oncology	2015	22
cancer	25405807	1956	Wang Z	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.	PloS one	2014	31
cancer	25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
cancer	25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
cancer	25468140	1956	Kalia M	Biomarkers for personalized oncology: recent advances and future challenges.	Metabolism	2015	32
cancer	25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
cancer	25492084	1956	Keck MK	Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.	Clinical cancer research 	2015	30
cancer	25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
cancer	25579803	1956	Gustavsson B	A review of the evolution of systemic chemotherapy in the management of colorectal cancer.	Clinical colorectal cancer	2015	29
cancer	25583986	1956	Liu Z	A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.	The Journal of biological chemistry	2015	16
cancer	25586468	1956	Schuster J	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.	Neuro-oncology	2015	54
cancer	25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
cancer	25589621	1956	Yaeger R	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.	Clinical cancer research 	2015	39
cancer	25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
cancer	25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	18
cancer	25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
cancer	25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
cancer	25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
cancer	25629630	1956	Fillmore CM	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.	Nature	2015	49
cancer	25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
cancer	25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
cancer	25649416	1956	Stahl P	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.	BMC gastroenterology	2015	17
cancer	25662388	1956	Kim MY	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.	Lung cancer	2015	25
cancer	25667274	1956	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	33
cancer	25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
cancer	25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
cancer	25678824	1956	Coward JI	New perspectives on targeted therapy in ovarian cancer.	International journal of women's health	2015	16
cancer	25682441	1956	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	19
cancer	25689095	1956	Kumarakulasinghe NB	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015	16
cancer	25714397	1956	Stahlhut C	Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.	Cell cycle	2015	21
cancer	25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
cancer	25752815	1956	Chen J	Signaling pathways in HPV-associated cancers and therapeutic implications.	Reviews in medical virology	2015	15
cancer	25758528	1956	Niederst MJ	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.	Nature communications	2015	45
cancer	25769900	1956	Zhu G	Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.	The Journal of molecular diagnostics 	2015	22
cancer	25789560	1956	Xue M	Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells.	Journal of the American Chemical Society	2015	16
cancer	25795635	1956	Burotto M	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.	The oncologist	2015	20
cancer	25805821	1956	Kaszuba K	N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
cancer	25807485	1956	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	63
cancer	25807554	1956	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	15
cancer	25829397	1956	Mok T	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.	Clinical cancer research 	2015	43
cancer	25832655	1956	Jie HB	CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.	Cancer research	2015	33
cancer	25843712	1956	Blakely CM	NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.	Cell reports	2015	22
cancer	25870145	1956	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	30
cancer	25882755	1956	Watanabe M	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.	Clinical cancer research 	2015	37
cancer	25892145	1956	Machiels JP	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head &amp;amp; Neck 1): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	39
cancer	25895031	1956	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	32
cancer	25897154	1956	Lee CK	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.	Journal of clinical oncology 	2015	32
cancer	25904751	1956	Rosenthal EL	Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.	Clinical cancer research 	2015	33
cancer	25923549	1956	Jänne PA	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.	The New England journal of medicine	2015	228
cancer	25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
cancer	25926053	1956	Medico E	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.	Nature communications	2015	29
cancer	25934077	1956	Piotrowska Z	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.	Cancer discovery	2015	55
cancer	25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
cancer	25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
cancer	25961939	1956	Moriarity BS	A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.	Nature genetics	2015	36
cancer	25963091	1956	Thomas A	Refining the treatment of NSCLC according to histological and molecular subtypes.	Nature reviews. Clinical oncology	2015	24
cancer	25964297	1956	Niederst MJ	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.	Clinical cancer research 	2015	41
cancer	25964637	1956	Ettinger DS	Non-Small Cell Lung Cancer, Version 6.2015.	Journal of the National Comprehensive Cancer Network 	2015	68
cancer	25979833	1956	Brulé SY	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.	European journal of cancer	2015	22
cancer	25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
cancer	26014294	1956	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	26
cancer	26024796	1956	Cooper WA	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.	Lung cancer	2015	29
cancer	26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
cancer	26036643	1956	Tricker EM	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	Cancer discovery	2015	28
cancer	26045340	1956	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	52
cancer	26105600	1956	Wu YL	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.	Annals of oncology 	2015	30
cancer	26121317	1956	Stewart RL	Clinical significance of the integrin α6β4 in human malignancies.	Laboratory investigation; a journal of technical methods and pathology	2015	24
cancer	26124204	1956	Della Corte CM	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.	Clinical cancer research 	2015	18
cancer	26141208	1956	Zhou C	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).	Annals of oncology 	2015	39
cancer	26149886	1956	Devarakonda S	Genomic alterations in lung adenocarcinoma.	The Lancet. Oncology	2015	20
cancer	26159065	1956	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	49
cancer	26169611	1956	Scagliotti G	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	34
cancer	26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
cancer	26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
cancer	26227959	1956	Sun W	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.	Journal of hematology and oncology	2015	25
cancer	26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
cancer	26267324	1956	Riquelme I	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.	Oncotarget	2015	18
cancer	26269204	1956	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	26
cancer	26295376	1956	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	25
cancer	26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
cancer	26324367	1956	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	47
cancer	26330164	1956	Caruso HG	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.	Cancer research	2015	36
cancer	26351341	1956	Sacco AG	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.	Journal of clinical oncology 	2015	22
cancer	26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
cancer	26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
cancer	26370354	1956	Tan CS	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.	The Lancet. Oncology	2015	35
cancer	26392303	1956	Misale S	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.	Nature communications	2015	17
cancer	26392535	1956	Kamburov A	Comprehensive assessment of cancer missense mutation clustering in protein structures.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
cancer	26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	51
cancer	26416997	1956	Cai W	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.	Journal of clinical oncology 	2015	21
cancer	26434585	1956	Schneider MR	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.	Oncogene	2016	12
cancer	26438111	1956	Allegra CJ	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.	Journal of clinical oncology 	2016	31
cancer	26446944	1956	Sundaresan TK	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.	Clinical cancer research 	2016	45
cancer	26459174	1956	Paweletz CP	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.	Clinical cancer research 	2016	19
cancer	26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
cancer	26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
cancer	26494259	1956	Thress KS	EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.	Lung cancer	2015	39
cancer	26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
cancer	26537995	1956	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	19
cancer	26577492	1956	Sueoka-Aragane N	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.	Cancer science	2016	13
cancer	26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
cancer	26598545	1956	Gebhart G	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.	Annals of oncology 	2016	19
cancer	26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
cancer	26646759	1956	Schuler M	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.	Annals of oncology 	2016	14
cancer	26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
cancer	26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
cancer	26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
cancer	26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
cancer	26735353	1956	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	16
cancer	26755650	1956	Lee JY	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).	Oncotarget	2016	16
cancer	26777916	1956	Barlesi F	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	Lancet	2016	43
cancer	26789630	1956	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	13
cancer	26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
cancer	26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
cancer	26824988	1956	de Melo Gagliato D	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.	Oncotarget	2016	21
cancer	26828195	1956	Hata AN	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.	Nature medicine	2016	57
cancer	26832883	1956	Mukai S	Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer.	Annals of surgical oncology	2017	5
cancer	26843189	1956	Arena S	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.	Science translational medicine	2016	11
cancer	26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
cancer	26867973	1956	Zheng D	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.	Scientific reports	2016	29
cancer	26874901	1956	Chan A	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2016	13
cancer	26890676	1956	Veitch AM	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.	Endoscopy	2016	12
cancer	26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
cancer	26926684	1956	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	12
cancer	26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
cancer	26968708	1956	Feng K	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.	Science China. Life sciences	2016	14
cancer	27060149	1956	Lai Z	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.	Nucleic acids research	2016	12
cancer	27071706	1956	Wang S	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.	Journal of hematology and oncology	2016	29
cancer	27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
cancer	27117702	1956	Lin S	The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.	Molecular cell	2016	23
cancer	27354477	1956	Oxnard GR	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	31
cancer	27688480	1956	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	7
cancer	27718847	1956	Reck M	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	The New England journal of medicine	2016	147
cancer	27745820	1956	Langer CJ	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.	The Lancet. Oncology	2016	29
cancer	27836716	1956	Gettinger SN	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.	The Lancet. Oncology	2016	13
cancer	27922044	1956	Punt CJ	From tumour heterogeneity to advances in precision treatment of colorectal cancer.	Nature reviews. Clinical oncology	2017	5
cancer	27959700	1956	Mok TS	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.	The New England journal of medicine	2017	42
cardiovascular	17082756	1956	Chonchol M	25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey.	Kidney international	2007	63
cardiovascular	18325048	1956	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	61
cardiovascular	19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
cardiovascular	19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
cardiovascular	19429932	1956	Mirza MA	Relationship between circulating FGF23 and total body atherosclerosis in the community.	Nephrology, dialysis, transplantation 	2009	51
cardiovascular	20018733	1956	Chan G	Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility.	Proceedings of the National Academy of Sciences of the United States of America	2009	56
cardiovascular	20130423	1956	Lurje G	EGFR signaling and drug discovery.	Oncology	2009	103
cardiovascular	20189275	1956	Matsushita K	Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.	American journal of kidney diseases 	2010	64
cardiovascular	20671236	1956	Zhu WZ	Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.	Circulation research	2010	59
cardiovascular	21355053	1956	Rosolowsky ET	Risk for ESRD in type 1 diabetes remains high despite renoprotection.	Journal of the American Society of Nephrology 	2011	52
cardiovascular	21610077	1956	Kinney SM	Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes.	The Journal of biological chemistry	2011	46
cardiovascular	21646496	1956	Alonso A	Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.	Circulation	2011	73
cardiovascular	21976538	1956	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	75
cardiovascular	22898678	1956	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	56
cardiovascular	23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
cardiovascular	25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
cardiovascular	25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
cardiovascular	25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
cardiovascular	25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
cardiovascular	25589610	1956	Schanstra JP	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.	Journal of the American Society of Nephrology 	2015	21
cardiovascular	26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
cardiovascular	26229137	1956	Stubbs JR	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.	Journal of the American Society of Nephrology 	2016	27
cardiovascular	26295376	1956	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	25
cardiovascular	26890676	1956	Veitch AM	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.	Endoscopy	2016	12
cardiovascular	26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
cardiovascular	27383068	1956	Hill NR	Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.	PloS one	2016	21
diabetes	21189092	1956	de Boer RA	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.	Annals of medicine	2011	74
diabetes	21338849	1956	Stevens LA	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP).	American journal of kidney diseases 	2011	38
diabetes	21355053	1956	Rosolowsky ET	Risk for ESRD in type 1 diabetes remains high despite renoprotection.	Journal of the American Society of Nephrology 	2011	52
diabetes	22112968	1956	He X	Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.	Annals of oncology 	2012	49
diabetes	23687356	1956	Rhee EP	A combined epidemiologic and metabolomic approach improves CKD prediction.	Journal of the American Society of Nephrology 	2013	40
diabetes	24429397	1956	Niewczas MA	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.	Kidney international	2014	27
diabetes	24722445	1956	de Zeeuw D	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.	Journal of the American Society of Nephrology 	2014	36
diabetes	24970885	1956	Navarro-González JF	Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.	Journal of the American Society of Nephrology 	2015	18
diabetes	25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
diabetes	25589610	1956	Schanstra JP	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.	Journal of the American Society of Nephrology 	2015	21
diabetes	25677388	1956	Banerjee T	High Dietary Acid Load Predicts ESRD among Adults with CKD.	Journal of the American Society of Nephrology 	2015	17
diabetes	25726255	1956	Higuchi C	Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes.	Metabolism	2015	20
diabetes	25805821	1956	Kaszuba K	N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
diabetes	27539604	1956	Heerspink HJ	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.	Journal of the American Society of Nephrology 	2017	13
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	9041202	1956	Relf M	Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.	Cancer research	1997	128
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	9831867	1956	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	109
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	10873065	1956	Huang SM	Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.	Clinical cancer research 	2000	98
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	11426640	1956	Mendelsohn J	The EGF receptor family as targets for cancer therapy.	Oncogene	2000	206
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	12499279	1956	Ang KK	Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.	Cancer research	2002	224
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	12860957	1956	Mendelsohn J	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.	Journal of clinical oncology 	2003	184
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	14638850	1956	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	122
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	15746047	1956	Heimberger AB	Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.	Clinical cancer research 	2005	134
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	15833866	1956	Chinnaiyan P	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).	Cancer research	2005	84
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	16024112	1956	Dittmann K	Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity.	Radiotherapy and oncology 	2005	67
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	17290067	1956	Sequist LV	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.	Journal of clinical oncology 	2007	144
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18211286	1956	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	54
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18380996	1956	Marur S	Head and neck cancer: changing epidemiology, diagnosis, and treatment.	Mayo Clinic proceedings	2008	84
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18421051	1956	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	97
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18452692	1956	Molina JR	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.	Mayo Clinic proceedings	2008	357
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18782861	1956	Tao RH	All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.	Journal of cell science	2008	69
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	18955445	1956	Brown PD	Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.	Journal of clinical oncology 	2008	61
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	19075262	1956	Prados MD	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.	Journal of clinical oncology 	2009	88
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	19091906	1956	Aerts HJ	Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.	Journal of nuclear medicine 	2009	53
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	19252415	1956	Golding SE	Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.	Cancer biology and therapy	2009	49
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	19480968	1956	Kuremsky JG	Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.	International journal of radiation oncology, biology, physics	2009	56
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	19720911	1956	Millar EK	Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.	Journal of clinical oncology 	2009	60
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	19960228	1956	Peereboom DM	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.	Journal of neuro-oncology	2010	57
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	20150372	1956	Raizer JJ	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.	Neuro-oncology	2010	56
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	20194857	1956	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	212
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	21266349	1956	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	65
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	21555682	1956	Blumenschein GR Jr	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.	Journal of clinical oncology 	2011	46
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	21630130	1956	Lacouture ME	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.	Supportive care in cancer 	2011	37
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	21730270	1956	Yatabe Y	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.	Journal of clinical oncology 	2011	46
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	21881553	1956	Goraya N	Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy.	Kidney international	2012	40
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	21990576	1956	Terwisscha van Scheltinga AG	Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.	Journal of nuclear medicine 	2011	51
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	22144946	1956	Karar J	PI3K/AKT/mTOR Pathway in Angiogenesis.	Frontiers in molecular neuroscience	2011	107
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	22261334	1956	Han W	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.	Cancer letters	2012	64
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	22452803	1956	Fokas E	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.	Radiation oncology	2012	30
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	22464348	1956	Couraud S	Lung cancer in never smokers--a review.	European journal of cancer	2012	51
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23172311	1956	Huang S	Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.	Cancer research	2013	34
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23401448	1956	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	27
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23576557	1956	Keysar SB	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.	Cancer research	2013	26
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23830194	1956	Brand TM	Nuclear EGFR as a molecular target in cancer.	Radiotherapy and oncology 	2013	38
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	23894143	1956	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	32
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	24165158	1956	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	29
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	24429397	1956	Niewczas MA	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.	Kidney international	2014	27
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	24621885	1956	Zhang Y	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.	PloS one	2014	21
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	24981256	1956	Camidge DR	Acquired resistance to TKIs in solid tumours: learning from lung cancer.	Nature reviews. Clinical oncology	2014	107
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	24986882	1956	Grusch M	Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.	The EMBO journal	2014	29
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25091798	1956	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	30
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25136066	1956	Brand TM	AXL mediates resistance to cetuximab therapy.	Cancer research	2014	27
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25349291	1956	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	23
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25492084	1956	Keck MK	Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.	Clinical cancer research 	2015	30
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25596659	1956	Giralt J	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	21
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	25677388	1956	Banerjee T	High Dietary Acid Load Predicts ESRD among Adults with CKD.	Journal of the American Society of Nephrology 	2015	17
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
hot+or+cold+or+alkaline+condition+or+acidic+condition+or+hypersaline+or+radiation	27688480	1956	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	7
food+or+nutrition+or+nutrients	17082756	1956	Chonchol M	25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey.	Kidney international	2007	63
food+or+nutrition+or+nutrients	17827454	1956	Harari PM	Biology of interactions: antiepidermal growth factor receptor agents.	Journal of clinical oncology 	2007	56
food+or+nutrition+or+nutrients	18211286	1956	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	54
food+or+nutrition+or+nutrients	20679611	1956	Yap TA	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.	Journal of clinical oncology 	2010	77
food+or+nutrition+or+nutrients	21881553	1956	Goraya N	Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy.	Kidney international	2012	40
food+or+nutrition+or+nutrients	22162641	1956	Ou SH	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.	Drug design, development and therapy	2011	37
food+or+nutrition+or+nutrients	22658319	1956	Hurvitz SA	Current approaches and future directions in the treatment of HER2-positive breast cancer.	Cancer treatment reviews	2013	29
food+or+nutrition+or+nutrients	23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
food+or+nutrition+or+nutrients	24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
food+or+nutrition+or+nutrients	24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
food+or+nutrition+or+nutrients	24722445	1956	de Zeeuw D	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.	Journal of the American Society of Nephrology 	2014	36
food+or+nutrition+or+nutrients	24868098	1956	Khozin S	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	The oncologist	2014	20
food+or+nutrition+or+nutrients	25492084	1956	Keck MK	Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.	Clinical cancer research 	2015	30
food+or+nutrition+or+nutrients	25677388	1956	Banerjee T	High Dietary Acid Load Predicts ESRD among Adults with CKD.	Journal of the American Society of Nephrology 	2015	17
food+or+nutrition+or+nutrients	25795635	1956	Burotto M	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.	The oncologist	2015	20
food+or+nutrition+or+nutrients	26984449	1956	Kazandjian D	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.	The oncologist	2016	23
food+or+nutrition+or+nutrients	27026676	1956	Sul J	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.	The oncologist	2016	12
glycoproteins	11836430	1956	Simmons G	Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.	Journal of virology	2002	85
glycoproteins	12359858	1956	Wang F	Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.	Journal of the National Cancer Institute	2002	111
glycoproteins	12670923	1956	Aguirre-Ghiso JA	ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).	Cancer research	2003	107
glycoproteins	15057284	1956	Qian X	E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.	The EMBO journal	2004	106
glycoproteins	15153612	1956	Chen Z	Characterization of putative stem cell phenotype in human limbal epithelia.	Stem cells	2004	116
glycoproteins	15158434	1956	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	70
glycoproteins	15345710	1956	Laederich MB	The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.	The Journal of biological chemistry	2004	75
glycoproteins	16361555	1956	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	161
glycoproteins	16424029	1956	Witta SE	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.	Cancer research	2006	137
glycoproteins	16565089	1956	Bourguignon LY	Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells.	The Journal of biological chemistry	2006	74
glycoproteins	16980555	1956	Zhen G	IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production.	American journal of respiratory cell and molecular biology	2007	74
glycoproteins	17146782	1956	Rakha EA	Prognostic markers in triple-negative breast cancer.	Cancer	2007	262
glycoproteins	17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
glycoproteins	17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
glycoproteins	17664471	1956	Khambata-Ford S	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.	Journal of clinical oncology 	2007	291
glycoproteins	18317468	1956	Sklar P	Whole-genome association study of bipolar disorder.	Molecular psychiatry	2008	209
glycoproteins	18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
glycoproteins	19490536	1956	Stuffers S	Multivesicular endosome biogenesis in the absence of ESCRTs.	Traffic	2009	58
glycoproteins	19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
glycoproteins	20012924	1956	McConkey DJ	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.	Cancer metastasis reviews	2009	81
glycoproteins	20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
glycoproteins	20562913	1956	Gan Y	Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.	Oncogene	2010	73
glycoproteins	20798686	1956	Li QQ	Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.	Cell death and differentiation	2011	40
glycoproteins	21273060	1956	Krumbach R	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.	European journal of cancer	2011	39
glycoproteins	21407195	1956	Maretzky T	Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.	Nature communications	2011	38
glycoproteins	21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
glycoproteins	21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
glycoproteins	22191652	1956	Zhang Y	PET tracers based on Zirconium-89.	Current radiopharmaceuticals	2011	40
glycoproteins	22194472	1956	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	122
glycoproteins	22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
glycoproteins	22508830	1956	Witta SE	Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.	Journal of clinical oncology 	2012	50
glycoproteins	22591372	1956	Gorges TM	Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.	BMC cancer	2012	110
glycoproteins	22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
glycoproteins	23070115	1956	Uchida H	Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.	Molecular therapy 	2013	26
glycoproteins	23186290	1956	Truong TH	Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation.	Biochemistry	2012	42
glycoproteins	23333074	1956	Zaiss DM	Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.	Immunity	2013	49
glycoproteins	23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
glycoproteins	23555746	1956	Luca AC	Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines.	PloS one	2013	36
glycoproteins	23645635	1956	Rizvi I	Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.	Proceedings of the National Academy of Sciences of the United States of America	2013	32
glycoproteins	23653350	1956	Balanis N	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.	The Journal of biological chemistry	2013	29
glycoproteins	23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
glycoproteins	24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
glycoproteins	24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
glycoproteins	25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
glycoproteins	25926053	1956	Medico E	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.	Nature communications	2015	29
glycoproteins	26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
kidney+or+urine	15782206	1956	Chen I	Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase.	Nature methods	2005	155
kidney+or+urine	17082756	1956	Chonchol M	25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey.	Kidney international	2007	63
kidney+or+urine	18761338	1956	Zeng F	The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology.	Experimental cell research	2009	48
kidney+or+urine	19429932	1956	Mirza MA	Relationship between circulating FGF23 and total body atherosclerosis in the community.	Nephrology, dialysis, transplantation 	2009	51
kidney+or+urine	20189275	1956	Matsushita K	Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.	American journal of kidney diseases 	2010	64
kidney+or+urine	20416999	1956	Horio M	Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates.	American journal of kidney diseases 	2010	52
kidney+or+urine	21107446	1956	Stevens LA	Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities.	Kidney international	2011	45
kidney+or+urine	21338849	1956	Stevens LA	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP).	American journal of kidney diseases 	2011	38
kidney+or+urine	21355053	1956	Rosolowsky ET	Risk for ESRD in type 1 diabetes remains high despite renoprotection.	Journal of the American Society of Nephrology 	2011	52
kidney+or+urine	21646496	1956	Alonso A	Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.	Circulation	2011	73
kidney+or+urine	21852664	1956	Thomas G	Metabolic syndrome and kidney disease: a systematic review and meta-analysis.	Clinical journal of the American Society of Nephrology 	2011	89
kidney+or+urine	21881553	1956	Goraya N	Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy.	Kidney international	2012	40
kidney+or+urine	23045285	1956	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	35
kidney+or+urine	23275377	1956	Bansal N	Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease.	Circulation	2013	29
kidney+or+urine	23687356	1956	Rhee EP	A combined epidemiologic and metabolomic approach improves CKD prediction.	Journal of the American Society of Nephrology 	2013	40
kidney+or+urine	24429397	1956	Niewczas MA	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.	Kidney international	2014	27
kidney+or+urine	24652789	1956	Lu JL	Association of body mass index with outcomes in patients with CKD.	Journal of the American Society of Nephrology 	2014	33
kidney+or+urine	24722445	1956	de Zeeuw D	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.	Journal of the American Society of Nephrology 	2014	36
kidney+or+urine	24904092	1956	Irazabal MV	Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.	Journal of the American Society of Nephrology 	2015	24
kidney+or+urine	24970885	1956	Navarro-González JF	Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.	Journal of the American Society of Nephrology 	2015	18
kidney+or+urine	25556173	1956	Loupy A	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.	Journal of the American Society of Nephrology 	2015	20
kidney+or+urine	25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
kidney+or+urine	25589610	1956	Schanstra JP	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.	Journal of the American Society of Nephrology 	2015	21
kidney+or+urine	25677388	1956	Banerjee T	High Dietary Acid Load Predicts ESRD among Adults with CKD.	Journal of the American Society of Nephrology 	2015	17
kidney+or+urine	26040904	1956	Solé C	miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis.	Nephrology, dialysis, transplantation 	2015	21
kidney+or+urine	26229137	1956	Stubbs JR	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.	Journal of the American Society of Nephrology 	2016	27
kidney+or+urine	26912543	1956	Torres VE	Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.	Clinical journal of the American Society of Nephrology 	2016	10
kidney+or+urine	27383068	1956	Hill NR	Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.	PloS one	2016	21
kidney+or+urine	27745820	1956	Langer CJ	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.	The Lancet. Oncology	2016	29
liver+or+hepatic	10722725	1956	Jo M	Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.	The Journal of biological chemistry	2000	104
liver+or+hepatic	12124174	1956	Liu D	EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.	Cancer cell	2002	103
liver+or+hepatic	16170173	1956	Philip PA	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.	Journal of clinical oncology 	2005	94
liver+or+hepatic	17030071	1956	Malhi H	Cholangiocarcinoma: modern advances in understanding a deadly old disease.	Journal of hepatology	2006	65
liver+or+hepatic	17050876	1956	Dragovich T	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.	Journal of clinical oncology 	2006	75
liver+or+hepatic	17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
liver+or+hepatic	17623837	1956	Thomas MB	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.	Cancer	2007	69
liver+or+hepatic	18087285	1956	Yoshikawa D	Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.	British journal of cancer	2008	79
liver+or+hepatic	18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
liver+or+hepatic	18821591	1956	Llovet JM	Molecular targeted therapies in hepatocellular carcinoma.	Hepatology	2008	267
liver+or+hepatic	19169683	1956	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	59
liver+or+hepatic	19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
liver+or+hepatic	19706799	1956	Desbois-Mouthon C	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.	Clinical cancer research 	2009	57
liver+or+hepatic	19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
liver+or+hepatic	20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
liver+or+hepatic	20736298	1956	Cameron D	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.	The oncologist	2010	49
liver+or+hepatic	20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
liver+or+hepatic	21253578	1956	Gu TL	Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.	PloS one	2011	89
liver+or+hepatic	21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
liver+or+hepatic	21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
liver+or+hepatic	22173549	1956	Vermaat JS	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.	Clinical cancer research 	2012	44
liver+or+hepatic	22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
liver+or+hepatic	22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
liver+or+hepatic	22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
liver+or+hepatic	22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
liver+or+hepatic	22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
liver+or+hepatic	23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
liver+or+hepatic	23045285	1956	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	35
liver+or+hepatic	23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
liver+or+hepatic	23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
liver+or+hepatic	23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
liver+or+hepatic	23633480	1956	Chettouh H	Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.	Cancer research	2013	32
liver+or+hepatic	24122263	1956	Cummings MC	Metastatic progression of breast cancer: insights from 50 years of autopsies.	The Journal of pathology	2014	25
liver+or+hepatic	24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
liver+or+hepatic	24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
liver+or+hepatic	24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
liver+or+hepatic	24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
liver+or+hepatic	24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
liver+or+hepatic	24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
liver+or+hepatic	25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
liver+or+hepatic	25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
liver+or+hepatic	25726255	1956	Higuchi C	Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes.	Metabolism	2015	20
liver+or+hepatic	25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
liver+or+hepatic	25979833	1956	Brulé SY	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.	European journal of cancer	2015	22
liver+or+hepatic	26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
liver+or+hepatic	26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
liver+or+hepatic	26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
liver+or+hepatic	26890676	1956	Veitch AM	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.	Endoscopy	2016	12
liver+or+hepatic	27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
rat+or+mouse	2999974	1956	Coussens L	Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.	Science	1985	261
rat+or+mouse	9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
rat+or+mouse	9403702	1956	Petit AM	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.	The American journal of pathology	1997	115
rat+or+mouse	9815926	1956	Goldstein NI	Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.	Clinical cancer research 	1995	117
rat+or+mouse	10075741	1956	Biscardi JS	c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.	The Journal of biological chemistry	1999	174
rat+or+mouse	10202547	1956	Hatten ME	Central nervous system neuronal migration.	Annual review of neuroscience	1999	158
rat+or+mouse	10722725	1956	Jo M	Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.	The Journal of biological chemistry	2000	104
rat+or+mouse	10760290	1956	Grandis JR	Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2000	149
rat+or+mouse	10815932	1956	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	107
rat+or+mouse	10873065	1956	Huang SM	Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.	Clinical cancer research 	2000	98
rat+or+mouse	11156248	1956	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	94
rat+or+mouse	11420660	1956	Garcia R	Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.	Oncogene	2001	164
rat+or+mouse	11426640	1956	Mendelsohn J	The EGF receptor family as targets for cancer therapy.	Oncogene	2000	206
rat+or+mouse	11431323	1956	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	86
rat+or+mouse	11431346	1956	Viloria-Petit A	Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.	Cancer research	2001	110
rat+or+mouse	11595683	1956	Ciardiello F	A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.	Clinical cancer research 	2001	135
rat+or+mouse	11836430	1956	Simmons G	Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.	Journal of virology	2002	85
rat+or+mouse	12183421	1956	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	158
rat+or+mouse	12297049	1956	Garrett TP	Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.	Cell	2002	188
rat+or+mouse	12359858	1956	Wang F	Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.	Journal of the National Cancer Institute	2002	111
rat+or+mouse	12384534	1956	Wakeling AE	ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.	Cancer research	2002	132
rat+or+mouse	12435727	1956	Andl CD	Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo.	The Journal of biological chemistry	2003	90
rat+or+mouse	12499279	1956	Ang KK	Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.	Cancer research	2002	224
rat+or+mouse	15173008	1956	Rabindran SK	Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.	Cancer research	2004	92
rat+or+mouse	15345710	1956	Laederich MB	The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.	The Journal of biological chemistry	2004	75
rat+or+mouse	15735034	1956	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	82
rat+or+mouse	15831234	1956	Giannini C	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.	Neuro-oncology	2005	158
rat+or+mouse	15833866	1956	Chinnaiyan P	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).	Cancer research	2005	84
rat+or+mouse	15994331	1956	Clayton AH	Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis.	The Journal of biological chemistry	2005	82
rat+or+mouse	16020518	1956	Means AL	Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.	Development	2005	106
rat+or+mouse	16452222	1956	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	213
rat+or+mouse	16540667	1956	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	61
rat+or+mouse	16624948	1956	Almeida CG	Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.	The Journal of neuroscience 	2006	75
rat+or+mouse	16730237	1956	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	125
rat+or+mouse	16980555	1956	Zhen G	IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production.	American journal of respiratory cell and molecular biology	2007	74
rat+or+mouse	17047074	1956	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	101
rat+or+mouse	17251932	1956	Ventura A	Restoration of p53 function leads to tumour regression in vivo.	Nature	2007	502
rat+or+mouse	17332301	1956	Kurai J	Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.	Clinical cancer research 	2007	86
rat+or+mouse	17360479	1956	Scott AM	A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.	Proceedings of the National Academy of Sciences of the United States of America	2007	59
rat+or+mouse	17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
rat+or+mouse	17646646	1956	Huang PH	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2007	147
rat+or+mouse	17699871	1956	Ritter CA	Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.	Clinical cancer research 	2007	166
rat+or+mouse	17974918	1956	Okawa T	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.	Genes and development	2007	65
rat+or+mouse	18024868	1956	Tabernero J	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2007	63
rat+or+mouse	18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
rat+or+mouse	18211286	1956	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	54
rat+or+mouse	18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
rat+or+mouse	18408761	1956	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	267
rat+or+mouse	18413800	1956	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	58
rat+or+mouse	18425114	1956	Al-Nedawi K	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.	Nature cell biology	2008	350
rat+or+mouse	18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
rat+or+mouse	18604200	1956	Kolev V	EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer.	Nature cell biology	2008	67
rat+or+mouse	18632642	1956	Lee-Hoeflich ST	A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.	Cancer research	2008	168
rat+or+mouse	18782861	1956	Tao RH	All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.	Journal of cell science	2008	69
rat+or+mouse	18829483	1956	Lo HW	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.	Clinical cancer research 	2008	65
rat+or+mouse	18922904	1956	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
rat+or+mouse	18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
rat+or+mouse	19060928	1956	Scaltriti M	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.	Oncogene	2009	103
rat+or+mouse	19089838	1956	Yang L	Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.	Small	2009	87
rat+or+mouse	19091906	1956	Aerts HJ	Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.	Journal of nuclear medicine 	2009	53
rat+or+mouse	19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
rat+or+mouse	19147502	1956	Griffero F	Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.	The Journal of biological chemistry	2009	49
rat+or+mouse	19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
rat+or+mouse	19234131	1956	Al-Nedawi K	Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2009	141
rat+or+mouse	19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
rat+or+mouse	19366827	1956	Yu J	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.	Clinical cancer research 	2009	54
rat+or+mouse	19412429	1956	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	48
rat+or+mouse	19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
rat+or+mouse	19421880	1956	Dembinski JL	Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.	Clinical and experimental metastasis	2009	60
rat+or+mouse	19433789	1956	O'Keeffe GC	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
rat+or+mouse	19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
rat+or+mouse	19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
rat+or+mouse	19625624	1956	Guo D	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2009	81
rat+or+mouse	19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
rat+or+mouse	19840943	1956	Demory ML	Epidermal growth factor receptor translocation to the mitochondria: regulation and effect.	The Journal of biological chemistry	2009	48
rat+or+mouse	19852961	1956	Goetz M	In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor.	Gastroenterology	2010	59
rat+or+mouse	19934333	1956	Scheuer W	Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.	Cancer research	2009	118
rat+or+mouse	20048743	1956	Zhou X	Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.	Laboratory investigation; a journal of technical methods and pathology	2010	94
rat+or+mouse	20049729	1956	Watt FM	Epidermal stem cell diversity and quiescence.	EMBO molecular medicine	2009	69
rat+or+mouse	20129249	1956	Turke AB	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.	Cancer cell	2010	279
rat+or+mouse	20621056	1956	Curtis SJ	Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.	Cell stem cell	2010	50
rat+or+mouse	20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
rat+or+mouse	20671236	1956	Zhu WZ	Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.	Circulation research	2010	59
rat+or+mouse	20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
rat+or+mouse	20858720	1956	Mazzoleni S	Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.	Cancer research	2010	65
rat+or+mouse	20861192	1956	Hochgräfe F	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.	Cancer research	2010	56
rat+or+mouse	20874002	1956	Katakowski M	MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma.	Cancer investigation	2010	47
rat+or+mouse	21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
rat+or+mouse	21220474	1956	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	37
rat+or+mouse	21253578	1956	Gu TL	Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.	PloS one	2011	89
rat+or+mouse	21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
rat+or+mouse	21266349	1956	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	65
rat+or+mouse	21266357	1956	Qi J	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	Cancer research	2011	49
rat+or+mouse	21273060	1956	Krumbach R	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.	European journal of cancer	2011	39
rat+or+mouse	21407195	1956	Maretzky T	Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.	Nature communications	2011	38
rat+or+mouse	21653320	1956	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	95
rat+or+mouse	21690342	1956	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	30
rat+or+mouse	21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
rat+or+mouse	21734175	1956	Chmielecki J	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.	Science translational medicine	2011	156
rat+or+mouse	21893191	1956	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	62
rat+or+mouse	21900593	1956	Yonesaka K	Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.	Science translational medicine	2011	134
rat+or+mouse	21909139	1956	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	36
rat+or+mouse	21990576	1956	Terwisscha van Scheltinga AG	Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.	Journal of nuclear medicine 	2011	51
rat+or+mouse	22065080	1956	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	44
rat+or+mouse	22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.	Oncogene	2012	52
rat+or+mouse	22186794	1956	Parato KA	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.	Molecular therapy 	2012	47
rat+or+mouse	22228822	1956	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	34
rat+or+mouse	22281684	1956	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	392
rat+or+mouse	22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
rat+or+mouse	22305568	1956	Spike BT	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.	Cell stem cell	2012	56
rat+or+mouse	22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
rat+or+mouse	22418026	1956	Oliveira S	Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.	Molecular imaging	2012	34
rat+or+mouse	22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
rat+or+mouse	22588883	1956	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	73
rat+or+mouse	22591372	1956	Gorges TM	Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.	BMC cancer	2012	110
rat+or+mouse	22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
rat+or+mouse	22834827	1956	Arora S	Honokiol: a novel natural agent for cancer prevention and therapy.	Current molecular medicine	2012	32
rat+or+mouse	22888144	1956	Solca F	Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.	The Journal of pharmacology and experimental therapeutics	2012	95
rat+or+mouse	22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
rat+or+mouse	22956577	1956	Overdijk MB	Crosstalk between human IgG isotypes and murine effector cells.	Journal of immunology	2012	39
rat+or+mouse	22961667	1956	Ercan D	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.	Cancer discovery	2012	77
rat+or+mouse	22964225	1956	Johnson H	Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.	Molecular and cellular proteomics 	2012	30
rat+or+mouse	23070115	1956	Uchida H	Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.	Molecular therapy 	2013	26
rat+or+mouse	23091115	1956	Byers LA	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.	Clinical cancer research 	2013	176
rat+or+mouse	23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
rat+or+mouse	23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
rat+or+mouse	23172311	1956	Huang S	Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.	Cancer research	2013	34
rat+or+mouse	23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	99
rat+or+mouse	23319610	1956	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
rat+or+mouse	23333074	1956	Zaiss DM	Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.	Immunity	2013	49
rat+or+mouse	23576557	1956	Keysar SB	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.	Cancer research	2013	26
rat+or+mouse	23607916	1956	Keysar SB	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.	Molecular oncology	2013	32
rat+or+mouse	23633480	1956	Chettouh H	Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.	Cancer research	2013	32
rat+or+mouse	23653350	1956	Balanis N	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.	The Journal of biological chemistry	2013	29
rat+or+mouse	23707073	1956	Babic I	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.	Cell metabolism	2013	30
rat+or+mouse	23729478	1956	Bardelli A	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.	Cancer discovery	2013	126
rat+or+mouse	23964022	1956	Giachino C	Molecular diversity subdivides the adult forebrain neural stem cell population.	Stem cells	2014	24
rat+or+mouse	24034250	1956	Wei Y	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.	Cell	2013	104
rat+or+mouse	24065731	1956	Walter AO	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.	Cancer discovery	2013	122
rat+or+mouse	24122793	1956	Troiani T	Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.	Clinical cancer research 	2013	36
rat+or+mouse	24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
rat+or+mouse	24165158	1956	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	29
rat+or+mouse	24310612	1956	Nathanson DA	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.	Science	2014	70
rat+or+mouse	24335959	1956	Huang WC	miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis.	Cancer research	2014	31
rat+or+mouse	24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
rat+or+mouse	24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
rat+or+mouse	24448239	1956	Luraghi P	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.	Cancer research	2014	23
rat+or+mouse	24553387	1956	Misale S	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.	Science translational medicine	2014	58
rat+or+mouse	24644001	1956	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	43
rat+or+mouse	24651011	1956	Arteaga CL	ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.	Cancer cell	2014	116
rat+or+mouse	24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	139
rat+or+mouse	24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
rat+or+mouse	24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
rat+or+mouse	24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
rat+or+mouse	24919575	1956	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	20
rat+or+mouse	24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
rat+or+mouse	25009231	1956	Rebouissou S	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.	Science translational medicine	2014	33
rat+or+mouse	25115304	1956	Sorich MJ	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.	Annals of oncology 	2015	68
rat+or+mouse	25136066	1956	Brand TM	AXL mediates resistance to cetuximab therapy.	Cancer research	2014	27
rat+or+mouse	25193862	1956	Wilson C	Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.	Oncotarget	2014	28
rat+or+mouse	25271963	1956	Finlay MR	Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.	Journal of medicinal chemistry	2014	27
rat+or+mouse	25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
rat+or+mouse	25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
rat+or+mouse	25583986	1956	Liu Z	A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.	The Journal of biological chemistry	2015	16
rat+or+mouse	25629630	1956	Fillmore CM	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.	Nature	2015	49
rat+or+mouse	25726255	1956	Higuchi C	Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes.	Metabolism	2015	20
rat+or+mouse	25807485	1956	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	63
rat+or+mouse	25870145	1956	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	30
rat+or+mouse	25873175	1956	Elkabets M	AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.	Cancer cell	2015	35
rat+or+mouse	25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
rat+or+mouse	26036643	1956	Tricker EM	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	Cancer discovery	2015	28
rat+or+mouse	26124204	1956	Della Corte CM	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.	Clinical cancer research 	2015	18
rat+or+mouse	26330164	1956	Caruso HG	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.	Cancer research	2015	36
rat+or+mouse	26392303	1956	Misale S	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.	Nature communications	2015	17
rat+or+mouse	26637667	1956	Lastwika KJ	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.	Cancer research	2016	31
rat+or+mouse	26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
rat+or+mouse	27688480	1956	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	7
pathology	3477813	1956	Wong AJ	Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.	Proceedings of the National Academy of Sciences of the United States of America	1987	173
pathology	3798106	1956	Slamon DJ	Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.	Science	1987	1881
pathology	9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
pathology	9403702	1956	Petit AM	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.	The American journal of pathology	1997	115
pathology	9831867	1956	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	109
pathology	10722725	1956	Jo M	Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.	The Journal of biological chemistry	2000	104
pathology	10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
pathology	10760290	1956	Grandis JR	Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2000	149
pathology	10815932	1956	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	107
pathology	10873065	1956	Huang SM	Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.	Clinical cancer research 	2000	98
pathology	10877829	1956	Puddicombe SM	Involvement of the epidermal growth factor receptor in epithelial repair in asthma.	FASEB journal 	2000	109
pathology	11156248	1956	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	94
pathology	11159180	1956	Specht K	Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.	The American journal of pathology	2001	91
pathology	11420660	1956	Garcia R	Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.	Oncogene	2001	164
pathology	11431323	1956	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	86
pathology	11431346	1956	Viloria-Petit A	Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.	Cancer research	2001	110
pathology	11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
pathology	11585753	1956	Moasser MM	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	Cancer research	2001	87
pathology	12124174	1956	Liu D	EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.	Cancer cell	2002	103
pathology	12183421	1956	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	158
pathology	12359858	1956	Wang F	Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.	Journal of the National Cancer Institute	2002	111
pathology	12429632	1956	Di Lorenzo G	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.	Clinical cancer research 	2002	88
pathology	12499279	1956	Ang KK	Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.	Cancer research	2002	224
pathology	12743152	1956	Cohen EE	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2003	98
pathology	12824187	1956	Buchanan FG	Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.	The Journal of biological chemistry	2003	104
pathology	12860957	1956	Mendelsohn J	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.	Journal of clinical oncology 	2003	184
pathology	12953099	1956	Hirsch FR	Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.	Journal of clinical oncology 	2003	238
pathology	14583498	1956	Shinojima N	Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.	Cancer research	2003	158
pathology	14638850	1956	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	122
pathology	14641026	1956	Fischer OM	EGFR signal transactivation in cancer cells.	Biochemical Society transactions	2003	95
pathology	14701768	1956	Soulieres D	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.	Journal of clinical oncology 	2004	145
pathology	14769856	1956	Liu H	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.	The Journal of cell biology	2004	93
pathology	15059883	1956	Nahta R	The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.	Cancer research	2004	112
pathology	15084238	1956	Arpino G	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.	Breast cancer research 	2004	105
pathology	15226328	1956	Xiong HQ	Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.	Journal of clinical oncology 	2004	91
pathology	15269313	1956	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	891
pathology	15310767	1956	Pérez-Soler R	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.	Journal of clinical oncology 	2004	151
pathology	15328174	1956	Nielsen TO	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.	Clinical cancer research 	2004	595
pathology	15492241	1956	Tracy S	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.	Cancer research	2004	86
pathology	15598946	1956	Spano JP	Impact of EGFR expression on colorectal cancer patient prognosis and survival.	Annals of oncology 	2005	70
pathology	15604253	1956	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	233
pathology	15665312	1956	Lo HW	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.	Cancer research	2005	92
pathology	15677699	1956	Chung KY	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.	Journal of clinical oncology 	2005	200
pathology	15681531	1956	Marchetti A	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.	Journal of clinical oncology 	2005	149
pathology	15709185	1956	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	94
pathology	15710947	1956	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	135
pathology	15728811	1956	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	832
pathology	15731348	1956	Engelman JA	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.	Proceedings of the National Academy of Sciences of the United States of America	2005	148
pathology	15735034	1956	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	82
pathology	15738541	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	175
pathology	15741570	1956	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	439
pathology	15746047	1956	Heimberger AB	Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.	Clinical cancer research 	2005	134
pathology	15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
pathology	15753462	1956	Herbst RS	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	86
pathology	15814656	1956	Shimizu M	(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.	Clinical cancer research 	2005	65
pathology	15831234	1956	Giannini C	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.	Neuro-oncology	2005	158
pathology	15920544	1956	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	76
pathology	15939921	1956	Baselga J	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.	Journal of clinical oncology 	2005	77
pathology	15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
pathology	16020518	1956	Means AL	Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.	Development	2005	106
pathology	16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
pathology	16043828	1956	Eberhard DA	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	Journal of clinical oncology 	2005	344
pathology	16043829	1956	Herbst RS	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2005	275
pathology	16051952	1956	Cappuzzo F	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.	Journal of clinical oncology 	2005	69
pathology	16115926	1956	Psyrri A	Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.	Clinical cancer research 	2005	90
pathology	16161046	1956	Hanawa M	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.	International journal of cancer	2006	67
pathology	16170173	1956	Philip PA	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.	Journal of clinical oncology 	2005	94
pathology	16204011	1956	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	119
pathology	16230383	1956	Baird K	Gene expression profiling of human sarcomas: insights into sarcoma biology.	Cancer research	2005	85
pathology	16314626	1956	Burtness B	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.	Journal of clinical oncology 	2005	166
pathology	16322287	1956	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	70
pathology	16333527	1956	Hiscox S	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.	Breast cancer research and treatment	2006	64
pathology	16361555	1956	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	161
pathology	16397019	1956	Diaz N	Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.	Clinical cancer research 	2006	78
pathology	16424029	1956	Witta SE	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.	Cancer research	2006	137
pathology	16452222	1956	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	213
pathology	16533778	1956	Rodríguez-Pinilla SM	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.	Clinical cancer research 	2006	68
pathology	16533793	1956	Tam IY	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.	Clinical cancer research 	2006	112
pathology	16540667	1956	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	61
pathology	16549822	1956	Takeuchi T	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.	Journal of clinical oncology 	2006	64
pathology	16565487	1956	Li YC	Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.	The American journal of pathology	2006	96
pathology	16730237	1956	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	125
pathology	16740687	1956	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	73
pathology	16757721	1956	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	957
pathology	16763281	1956	Kalyankrishna S	Epidermal growth factor receptor biology in head and neck cancer.	Journal of clinical oncology 	2006	160
pathology	16785471	1956	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	116
pathology	16837691	1956	Zakowski MF	EGFR mutations in small-cell lung cancers in patients who have never smoked.	The New England journal of medicine	2006	65
pathology	16912159	1956	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	96
pathology	16931954	1956	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	68
pathology	16938528	1956	Kim MJ	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.	Human pathology	2006	82
pathology	17047074	1956	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	101
pathology	17047648	1956	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	67
pathology	17050875	1956	Lenz HJ	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Journal of clinical oncology 	2006	90
pathology	17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	195
pathology	17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
pathology	17251932	1956	Ventura A	Restoration of p53 function leads to tumour regression in vivo.	Nature	2007	502
pathology	17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
pathology	17308062	1956	Nahta R	Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.	Molecular cancer therapeutics	2007	67
pathology	17403429	1956	Smith HO	GPR30: a novel indicator of poor survival for endometrial carcinoma.	American journal of obstetrics and gynecology	2007	74
pathology	17404082	1956	Shaffer DR	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	98
pathology	17440163	1956	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	98
pathology	17452677	1956	Moore MJ	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	Journal of clinical oncology 	2007	820
pathology	17470858	1956	Van Cutsem E	Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.	Journal of clinical oncology 	2007	381
pathology	17474783	1956	Huang X	Cancer cells assemble and align gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized surface Raman spectra: a potential cancer diagnostic marker.	Nano letters	2007	58
pathology	17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
pathology	17623837	1956	Thomas MB	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.	Cancer	2007	69
pathology	17663798	1956	Hoadley KA	EGFR associated expression profiles vary with breast tumor subtype.	BMC genomics	2007	101
pathology	17670948	1956	Franovic A	Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	68
pathology	17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
pathology	17888036	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	121
pathology	17894407	1956	De Luca A	The role of the EGFR signaling in tumor microenvironment.	Journal of cellular physiology	2008	89
pathology	17896140	1956	Lieto E	Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.	Annals of surgical oncology	2008	52
pathology	17922188	1956	Tan DS	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.	Breast cancer research and treatment	2008	60
pathology	17947225	1956	Rosell R	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.	Annals of oncology 	2008	60
pathology	17974556	1956	Cappuzzo F	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.	Annals of oncology 	2008	66
pathology	17974918	1956	Okawa T	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.	Genes and development	2007	65
pathology	18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
pathology	18087285	1956	Yoshikawa D	Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.	British journal of cancer	2008	79
pathology	18236164	1956	Barr S	Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.	Clinical and experimental metastasis	2008	70
pathology	18272912	1956	Tol J	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Annals of oncology 	2008	56
pathology	18281673	1956	Eberhard DA	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.	Journal of clinical oncology 	2008	67
pathology	18297114	1956	Wheeler DL	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.	Oncogene	2008	159
pathology	18303429	1956	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	71
pathology	18316557	1956	Cheang MC	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.	Clinical cancer research 	2008	299
pathology	18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
pathology	18362333	1956	Diehn M	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.	Proceedings of the National Academy of Sciences of the United States of America	2008	85
pathology	18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
pathology	18390971	1956	Sobrero AF	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	168
pathology	18391747	1956	Motoi N	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.	The American journal of surgical pathology	2008	77
pathology	18397279	1956	Kim MA	EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number.	Histopathology	2008	67
pathology	18408761	1956	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	267
pathology	18413800	1956	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	58
pathology	18421051	1956	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	97
pathology	18425114	1956	Al-Nedawi K	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.	Nature cell biology	2008	350
pathology	18437168	1956	Ladanyi M	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.	Modern pathology 	2008	71
pathology	18452692	1956	Molina JR	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.	Mayo Clinic proceedings	2008	357
pathology	18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
pathology	18486742	1956	Argiris A	Head and neck cancer.	Lancet	2008	285
pathology	18509184	1956	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	56
pathology	18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
pathology	18596266	1956	Maheswaran S	Detection of mutations in EGFR in circulating lung-cancer cells.	The New England journal of medicine	2008	402
pathology	18604200	1956	Kolev V	EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer.	Nature cell biology	2008	67
pathology	18612148	1956	Anders CK	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.	Journal of clinical oncology 	2008	140
pathology	18612151	1956	Hirsch FR	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.	Journal of clinical oncology 	2008	65
pathology	18632642	1956	Lee-Hoeflich ST	A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.	Cancer research	2008	168
pathology	18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
pathology	18836087	1956	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	80
pathology	18839307	1956	Viale G	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.	Breast cancer research and treatment	2009	51
pathology	18922904	1956	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
pathology	18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
pathology	18955454	1956	Di Leo A	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.	Journal of clinical oncology 	2008	92
pathology	18978815	1956	Pickl M	Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.	Oncogene	2009	84
pathology	19027483	1956	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	258
pathology	19047149	1956	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	65
pathology	19058255	1956	Xia W	Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.	Molecular carcinogenesis	2009	67
pathology	19073608	1956	Webster RJ	Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.	The Journal of biological chemistry	2009	138
pathology	19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
pathology	19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
pathology	19117999	1956	Huang F	The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.	Cancer research	2009	63
pathology	19150933	1956	Corkery B	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.	Annals of oncology 	2009	66
pathology	19169683	1956	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	59
pathology	19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
pathology	19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
pathology	19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
pathology	19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
pathology	19252415	1956	Golding SE	Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.	Cancer biology and therapy	2009	49
pathology	19276389	1956	Narayan M	Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.	Cancer research	2009	69
pathology	19276677	1956	Wheeler DL	Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.	Cancer biology and therapy	2009	55
pathology	19332730	1956	Natale RB	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.	Journal of clinical oncology 	2009	51
pathology	19346299	1956	Ross JS	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.	The oncologist	2009	199
pathology	19366827	1956	Yu J	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.	Clinical cancer research 	2009	54
pathology	19410716	1956	Pirker R	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.	Lancet	2009	294
pathology	19414683	1956	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	84
pathology	19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
pathology	19421880	1956	Dembinski JL	Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.	Clinical and experimental metastasis	2009	60
pathology	19433789	1956	O'Keeffe GC	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
pathology	19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
pathology	19480968	1956	Kuremsky JG	Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.	International journal of radiation oncology, biology, physics	2009	56
pathology	19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
pathology	19549916	1956	Di Vizio D	Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.	Cancer research	2009	77
pathology	19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
pathology	19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
pathology	19625624	1956	Guo D	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2009	81
pathology	19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
pathology	19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
pathology	19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	163
pathology	19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
pathology	19738166	1956	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
pathology	19738203	1956	Huang PH	Oncogenic EGFR signaling networks in glioma.	Science signaling	2009	92
pathology	19775602	1956	Dawson SJ	Triple negative breast cancers: clinical and prognostic implications.	European journal of cancer	2009	55
pathology	19786658	1956	Johnston S	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Journal of clinical oncology 	2009	191
pathology	19826477	1956	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
pathology	19917871	1956	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	139
pathology	19920198	1956	Gravendeel LA	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.	Cancer research	2009	128
pathology	19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
pathology	20012924	1956	McConkey DJ	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.	Cancer metastasis reviews	2009	81
pathology	20018733	1956	Chan G	Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility.	Proceedings of the National Academy of Sciences of the United States of America	2009	56
pathology	20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
pathology	20082448	1956	Rimawi MF	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.	Cancer	2010	45
pathology	20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
pathology	20100966	1956	Lynch TJ	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.	Journal of clinical oncology 	2010	103
pathology	20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
pathology	20108024	1956	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	44
pathology	20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
pathology	20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
pathology	20194857	1956	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	212
pathology	20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
pathology	20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
pathology	20431034	1956	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	105
pathology	20431349	1956	Witkiewicz AK	Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.	Cancer biology and therapy	2010	57
pathology	20479403	1956	Sequist LV	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	96
pathology	20501798	1956	O'Brien NA	Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.	Molecular cancer therapeutics	2010	83
pathology	20515495	1956	Krakstad C	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Molecular cancer	2010	65
pathology	20520800	1956	Blows FM	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.	PLoS medicine	2010	185
pathology	20551945	1956	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	61
pathology	20562913	1956	Gan Y	Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.	Oncogene	2010	73
pathology	20570559	1956	Herbst RS	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	2010	99
pathology	20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	979
pathology	20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
pathology	20621056	1956	Curtis SJ	Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.	Cell stem cell	2010	50
pathology	20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
pathology	20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
pathology	20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
pathology	20671236	1956	Zhu WZ	Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.	Circulation research	2010	59
pathology	20716591	1956	Sathornsumetee S	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.	Neuro-oncology	2010	48
pathology	20798686	1956	Li QQ	Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.	Cell death and differentiation	2011	40
pathology	20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
pathology	20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
pathology	20858720	1956	Mazzoleni S	Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.	Cancer research	2010	65
pathology	20861192	1956	Hochgräfe F	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.	Cancer research	2010	56
pathology	20874002	1956	Katakowski M	MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma.	Cancer investigation	2010	47
pathology	20887192	1956	da Cunha Santos G	EGFR mutations and lung cancer.	Annual review of pathology	2011	65
pathology	20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
pathology	20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	342
pathology	20943624	1956	Vermorken JB	Optimal treatment for recurrent/metastatic head and neck cancer.	Annals of oncology 	2010	51
pathology	21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
pathology	21048039	1956	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	54
pathology	21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
pathology	21062933	1956	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	47
pathology	21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
pathology	21160525	1956	Leemans CR	The molecular biology of head and neck cancer.	Nature reviews. Cancer	2011	466
pathology	21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
pathology	21168239	1956	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	39
pathology	21220474	1956	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	37
pathology	21220480	1956	Osborne CK	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.	Clinical cancer research 	2011	52
pathology	21248300	1956	Arcila ME	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.	Clinical cancer research 	2011	120
pathology	21248303	1956	Janjigian YY	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.	Clinical cancer research 	2011	45
pathology	21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
pathology	21303969	1956	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	87
pathology	21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
pathology	21430269	1956	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	619
pathology	21430781	1956	Bivona TG	FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.	Nature	2011	99
pathology	21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
pathology	21576636	1956	Spigel DR	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	40
pathology	21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
pathology	21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
pathology	21653320	1956	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	95
pathology	21670455	1956	Fukuoka M	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).	Journal of clinical oncology 	2011	294
pathology	21690342	1956	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	30
pathology	21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
pathology	21730270	1956	Yatabe Y	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.	Journal of clinical oncology 	2011	46
pathology	21764376	1956	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	79
pathology	21768463	1956	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	120
pathology	21775534	1956	Oxnard GR	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.	Clinical cancer research 	2011	83
pathology	21778164	1956	Heijink IH	Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery.	The European respiratory journal	2012	39
pathology	21788562	1956	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	61
pathology	21830014	1956	Tamimi RM	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	47
pathology	21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
pathology	21886163	1956	Breitbach CJ	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.	Nature	2011	138
pathology	21893191	1956	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	62
pathology	21909139	1956	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	36
pathology	21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
pathology	21926387	1956	Travis WD	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.	Proceedings of the American Thoracic Society	2011	71
pathology	21990576	1956	Terwisscha van Scheltinga AG	Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.	Journal of nuclear medicine 	2011	51
pathology	22020299	1956	Low-Nam ST	ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding.	Nature structural and molecular biology	2011	73
pathology	22025146	1956	Wells SA Jr	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2012	186
pathology	22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
pathology	22054879	1956	Travis WD	Pathology of lung cancer.	Clinics in chest medicine	2011	59
pathology	22056021	1956	Pirker R	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2012	132
pathology	22065080	1956	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	44
pathology	22119437	1956	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	35
pathology	22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
pathology	22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.	Oncogene	2012	52
pathology	22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
pathology	22173549	1956	Vermaat JS	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.	Clinical cancer research 	2012	44
pathology	22173704	1956	Krebs MG	Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.	Journal of thoracic oncology 	2012	101
pathology	22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
pathology	22189713	1956	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	48
pathology	22207554	1956	Park S	High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.	Histology and histopathology	2012	35
pathology	22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
pathology	22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
pathology	22228822	1956	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	34
pathology	22237264	1956	Sun PL	High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.	Journal of thoracic oncology 	2012	34
pathology	22261334	1956	Han W	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.	Cancer letters	2012	64
pathology	22281684	1956	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	392
pathology	22282308	1956	Cheng L	Molecular pathology of lung cancer: key to personalized medicine.	Modern pathology 	2012	41
pathology	22285168	1956	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	876
pathology	22305568	1956	Spike BT	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.	Cell stem cell	2012	56
pathology	22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
pathology	22370318	1956	Lee JS	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).	Journal of clinical oncology 	2012	70
pathology	22407829	1956	Perez-Moreno P	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.	Clinical cancer research 	2012	48
pathology	22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
pathology	22418700	1956	Lin NU	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.	Breast cancer research and treatment	2012	44
pathology	22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
pathology	22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
pathology	22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
pathology	22505743	1956	Navani N	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.	American journal of respiratory and critical care medicine	2012	53
pathology	22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
pathology	22579283	1956	Lee MJ	Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.	Cell	2012	180
pathology	22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
pathology	22591372	1956	Gorges TM	Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.	BMC cancer	2012	110
pathology	22611028	1956	Roselli M	Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.	Clinical cancer research 	2012	36
pathology	22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
pathology	22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	333
pathology	22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
pathology	22751098	1956	Zhang Z	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nature genetics	2012	263
pathology	22753918	1956	Ramalingam SS	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2012	63
pathology	22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
pathology	22778317	1956	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	54
pathology	22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
pathology	22797485	1956	Zhao X	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.	Respiration; international review of thoracic diseases	2013	30
pathology	22801742	1956	Doecke JD	Blood-based protein biomarkers for diagnosis of Alzheimer disease.	Archives of neurology	2012	65
pathology	22806307	1956	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	34
pathology	22810899	1956	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	32
pathology	22826274	1956	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	60
pathology	22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
pathology	22898037	1956	Argiris A	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.	Annals of oncology 	2013	34
pathology	22898678	1956	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	56
pathology	22949147	1956	Van Cutsem E	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.	Journal of clinical oncology 	2012	183
pathology	22977193	1956	Terashima M	Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.	Clinical cancer research 	2012	59
pathology	23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
pathology	23012302	1956	André F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	58
pathology	23014527	1956	Dogan S	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.	Clinical cancer research 	2012	74
pathology	23052255	1956	Suehara Y	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.	Clinical cancer research 	2012	35
pathology	23073759	1956	Masuda H	Role of epidermal growth factor receptor in breast cancer.	Breast cancer research and treatment	2012	81
pathology	23084121	1956	Nielsen DL	Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.	Breast	2013	26
pathology	23091115	1956	Byers LA	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.	Clinical cancer research 	2013	176
pathology	23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
pathology	23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	36
pathology	23149820	1956	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	49
pathology	23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
pathology	23154553	1956	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	36
pathology	23172555	1956	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	49
pathology	23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
pathology	23242438	1956	Yoshizawa A	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.	Journal of thoracic oncology 	2013	67
pathology	23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	99
pathology	23280481	1956	Chen CL	Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.	The Prostate	2013	44
pathology	23319610	1956	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
pathology	23333074	1956	Zaiss DM	Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.	Immunity	2013	49
pathology	23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
pathology	23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
pathology	23344264	1956	Yeh P	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.	Clinical cancer research 	2013	35
pathology	23358903	1956	Bayraktar S	Molecularly targeted therapies for metastatic triple-negative breast cancer.	Breast cancer research and treatment	2013	31
pathology	23361103	1956	Gonzalez de Castro D	Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.	Clinical pharmacology and therapeutics	2013	47
pathology	23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
pathology	23370315	1956	Hirsch FR	Epidermal growth factor receptor inhibition in lung cancer: status 2012.	Journal of thoracic oncology 	2013	26
pathology	23375249	1956	Heinemann V	Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.	Cancer treatment reviews	2013	28
pathology	23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
pathology	23401433	1956	Li T	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.	Journal of clinical oncology 	2013	86
pathology	23401443	1956	Travis WD	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.	Journal of clinical oncology 	2013	68
pathology	23401451	1956	Ohashi K	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.	Journal of clinical oncology 	2013	103
pathology	23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
pathology	23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
pathology	23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
pathology	23486266	1956	Russell PA	Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.	Journal of thoracic oncology 	2013	29
pathology	23551194	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Archives of pathology and laboratory medicine	2013	68
pathology	23552377	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	124
pathology	23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
pathology	23555746	1956	Luca AC	Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines.	PloS one	2013	36
pathology	23562183	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	60
pathology	23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
pathology	23576557	1956	Keysar SB	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.	Cancer research	2013	26
pathology	23584089	1956	Sadanandam A	A colorectal cancer classification system that associates cellular phenotype and responses to therapy.	Nature medicine	2013	186
pathology	23584090	1956	De Sousa E Melo F	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.	Nature medicine	2013	132
pathology	23636329	1956	Shen J	EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.	Nature	2013	100
pathology	23653350	1956	Balanis N	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.	The Journal of biological chemistry	2013	29
pathology	23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
pathology	23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
pathology	23729478	1956	Bardelli A	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.	Cancer discovery	2013	126
pathology	23733761	1956	Baselga J	Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.	Journal of clinical oncology 	2013	66
pathology	23777544	1956	Gan HK	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.	The FEBS journal	2013	46
pathology	23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
pathology	23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
pathology	23816963	1956	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	63
pathology	23816967	1956	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	49
pathology	23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	34
pathology	23872583	1956	Kanda R	Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.	Cancer research	2013	28
pathology	23888061	1956	Liu X	The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.	Journal of clinical pathology	2013	29
pathology	23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
pathology	23894143	1956	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	32
pathology	23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
pathology	23980091	1956	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	40
pathology	24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
pathology	24026012	1956	Giles KM	Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.	Molecular cancer therapeutics	2013	29
pathology	24065731	1956	Walter AO	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.	Cancer discovery	2013	122
pathology	24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
pathology	24105277	1956	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	38
pathology	24122263	1956	Cummings MC	Metastatic progression of breast cancer: insights from 50 years of autopsies.	The Journal of pathology	2014	25
pathology	24122793	1956	Troiani T	Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.	Clinical cancer research 	2013	36
pathology	24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
pathology	24165158	1956	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	29
pathology	24174329	1956	Clinical Lung Cancer Genome Project (CLCGP).	A genomics-based classification of human lung tumors.	Science translational medicine	2013	74
pathology	24199791	1956	Ahmad A	Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.	Journal of hematology and oncology	2013	29
pathology	24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
pathology	24248375	1956	Drake JM	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.	Proceedings of the National Academy of Sciences of the United States of America	2013	28
pathology	24335959	1956	Huang WC	miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis.	Cancer research	2014	31
pathology	24366937	1956	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	23
pathology	24378644	1956	Siegelin MD	Epidermal growth factor receptor mutations in lung adenocarcinoma.	Laboratory investigation; a journal of technical methods and pathology	2014	40
pathology	24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
pathology	24406864	1956	Park HS	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.	Modern pathology 	2014	33
pathology	24419411	1956	Shi Y	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).	Journal of thoracic oncology 	2014	113
pathology	24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
pathology	24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
pathology	24443522	1956	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	29
pathology	24448239	1956	Luraghi P	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.	Cancer research	2014	23
pathology	24458568	1956	Suda K	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	International journal of cancer	2014	22
pathology	24470557	1956	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	23
pathology	24508104	1956	André F	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).	The Lancet. Oncology	2014	55
pathology	24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
pathology	24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
pathology	24553385	1956	Bettegowda C	Detection of circulating tumor DNA in early- and late-stage human malignancies.	Science translational medicine	2014	385
pathology	24621885	1956	Zhang Y	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.	PloS one	2014	21
pathology	24626858	1956	Nagatsuma AK	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.	Gastric cancer 	2015	24
pathology	24644001	1956	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	43
pathology	24652789	1956	Lu JL	Association of body mass index with outcomes in patients with CKD.	Journal of the American Society of Nephrology 	2014	33
pathology	24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
pathology	24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
pathology	24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	139
pathology	24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
pathology	24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
pathology	24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
pathology	24687921	1956	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	26
pathology	24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
pathology	24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
pathology	24773774	1956	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	25
pathology	24816687	1956	Zhou X	MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.	PloS one	2014	24
pathology	24831979	1956	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	39
pathology	24857062	1956	Abrams J	National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	32
pathology	24886126	1956	Ma J	Targeting of erbB3 receptor to overcome resistance in cancer treatment.	Molecular cancer	2014	28
pathology	24895374	1956	Rohan TE	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.	Journal of the National Cancer Institute	2014	33
pathology	24904092	1956	Irazabal MV	Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.	Journal of the American Society of Nephrology 	2015	24
pathology	24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
pathology	24919575	1956	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	20
pathology	24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
pathology	25009014	1956	Azuma K	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.	Annals of oncology 	2014	66
pathology	25009231	1956	Rebouissou S	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.	Science translational medicine	2014	33
pathology	25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
pathology	25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
pathology	25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
pathology	25079552	1956	Cancer Genome Atlas Research Network.	Comprehensive molecular profiling of lung adenocarcinoma.	Nature	2014	567
pathology	25080476	1956	Müller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
pathology	25091798	1956	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	30
pathology	25136066	1956	Brand TM	AXL mediates resistance to cetuximab therapy.	Cancer research	2014	27
pathology	25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
pathology	25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
pathology	25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
pathology	25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
pathology	25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
pathology	25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
pathology	25311215	1956	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	42
pathology	25345567	1956	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	29
pathology	25349291	1956	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	23
pathology	25349974	1956	D'Incecco A	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	69
pathology	25394791	1956	Crystal AS	Patient-derived models of acquired resistance can identify effective drug combinations for cancer.	Science	2014	120
pathology	25405368	1956	Chiyomaru T	Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer.	International journal of oncology	2015	22
pathology	25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
pathology	25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
pathology	25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
pathology	25492084	1956	Keck MK	Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.	Clinical cancer research 	2015	30
pathology	25556173	1956	Loupy A	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.	Journal of the American Society of Nephrology 	2015	20
pathology	25567908	1956	Drilon A	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.	Clinical cancer research 	2015	30
pathology	25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
pathology	25579803	1956	Gustavsson B	A review of the evolution of systemic chemotherapy in the management of colorectal cancer.	Clinical colorectal cancer	2015	29
pathology	25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
pathology	25589621	1956	Yaeger R	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.	Clinical cancer research 	2015	39
pathology	25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
pathology	25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	18
pathology	25596659	1956	Giralt J	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	21
pathology	25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
pathology	25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
pathology	25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
pathology	25629630	1956	Fillmore CM	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.	Nature	2015	49
pathology	25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
pathology	25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
pathology	25649416	1956	Stahl P	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.	BMC gastroenterology	2015	17
pathology	25662388	1956	Kim MY	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.	Lung cancer	2015	25
pathology	25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
pathology	25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
pathology	25682441	1956	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	19
pathology	25689095	1956	Kumarakulasinghe NB	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015	16
pathology	25714397	1956	Stahlhut C	Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.	Cell cycle	2015	21
pathology	25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
pathology	25758528	1956	Niederst MJ	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.	Nature communications	2015	45
pathology	25807485	1956	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	63
pathology	25807554	1956	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	15
pathology	25832655	1956	Jie HB	CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.	Cancer research	2015	33
pathology	25843712	1956	Blakely CM	NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.	Cell reports	2015	22
pathology	25873175	1956	Elkabets M	AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.	Cancer cell	2015	35
pathology	25882755	1956	Watanabe M	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.	Clinical cancer research 	2015	37
pathology	25892145	1956	Machiels JP	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head &amp;amp; Neck 1): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	39
pathology	25895031	1956	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	32
pathology	25904751	1956	Rosenthal EL	Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.	Clinical cancer research 	2015	33
pathology	25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
pathology	25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
pathology	25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
pathology	25979833	1956	Brulé SY	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.	European journal of cancer	2015	22
pathology	25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
pathology	26014294	1956	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	26
pathology	26024796	1956	Cooper WA	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.	Lung cancer	2015	29
pathology	26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
pathology	26040904	1956	Solé C	miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis.	Nephrology, dialysis, transplantation 	2015	21
pathology	26045340	1956	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	52
pathology	26051236	1956	Yang JC	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	The Lancet. Oncology	2015	39
pathology	26121317	1956	Stewart RL	Clinical significance of the integrin α6β4 in human malignancies.	Laboratory investigation; a journal of technical methods and pathology	2015	24
pathology	26149886	1956	Devarakonda S	Genomic alterations in lung adenocarcinoma.	The Lancet. Oncology	2015	20
pathology	26159065	1956	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	49
pathology	26169611	1956	Scagliotti G	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	34
pathology	26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
pathology	26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
pathology	26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
pathology	26267324	1956	Riquelme I	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.	Oncotarget	2015	18
pathology	26269204	1956	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	26
pathology	26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
pathology	26318427	1956	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
pathology	26324367	1956	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	47
pathology	26330164	1956	Caruso HG	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.	Cancer research	2015	36
pathology	26351341	1956	Sacco AG	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.	Journal of clinical oncology 	2015	22
pathology	26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
pathology	26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
pathology	26370354	1956	Tan CS	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.	The Lancet. Oncology	2015	35
pathology	26392303	1956	Misale S	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.	Nature communications	2015	17
pathology	26392535	1956	Kamburov A	Comprehensive assessment of cancer missense mutation clustering in protein structures.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
pathology	26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	51
pathology	26416997	1956	Cai W	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.	Journal of clinical oncology 	2015	21
pathology	26434585	1956	Schneider MR	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.	Oncogene	2016	12
pathology	26446944	1956	Sundaresan TK	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.	Clinical cancer research 	2016	45
pathology	26459174	1956	Paweletz CP	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.	Clinical cancer research 	2016	19
pathology	26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
pathology	26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
pathology	26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
pathology	26537995	1956	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	19
pathology	26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
pathology	26598545	1956	Gebhart G	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.	Annals of oncology 	2016	19
pathology	26637667	1956	Lastwika KJ	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.	Cancer research	2016	31
pathology	26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
pathology	26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
pathology	26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
pathology	26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
pathology	26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
pathology	26735353	1956	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	16
pathology	26789630	1956	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	13
pathology	26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
pathology	26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
pathology	26828195	1956	Hata AN	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.	Nature medicine	2016	57
pathology	26832883	1956	Mukai S	Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer.	Annals of surgical oncology	2017	5
pathology	26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
pathology	26867973	1956	Zheng D	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.	Scientific reports	2016	29
pathology	26874901	1956	Chan A	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2016	13
pathology	26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
pathology	26926684	1956	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	12
pathology	26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
pathology	26968708	1956	Feng K	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.	Science China. Life sciences	2016	14
pathology	27071706	1956	Wang S	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.	Journal of hematology and oncology	2016	29
pathology	27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
pathology	27117702	1956	Lin S	The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.	Molecular cell	2016	23
plasma+or+serum	6157683	1956	Ushiro H	Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.	The Journal of biological chemistry	1980	190
plasma+or+serum	9831867	1956	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	109
plasma+or+serum	11897506	1956	Filardo EJ	Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer.	The Journal of steroid biochemistry and molecular biology	2002	91
plasma+or+serum	12429632	1956	Di Lorenzo G	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.	Clinical cancer research 	2002	88
plasma+or+serum	15738541	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	175
plasma+or+serum	15955900	1956	Burris HA 3rd	Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.	Journal of clinical oncology 	2005	123
plasma+or+serum	15994331	1956	Clayton AH	Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis.	The Journal of biological chemistry	2005	82
plasma+or+serum	16818687	1956	Kimura H	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.	Clinical cancer research 	2006	67
plasma+or+serum	17050876	1956	Dragovich T	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.	Journal of clinical oncology 	2006	75
plasma+or+serum	17082756	1956	Chonchol M	25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey.	Kidney international	2007	63
plasma+or+serum	17551144	1956	Taguchi F	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.	Journal of the National Cancer Institute	2007	68
plasma+or+serum	18188694	1956	Cameron D	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.	Breast cancer research and treatment	2008	143
plasma+or+serum	18211286	1956	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	54
plasma+or+serum	18425114	1956	Al-Nedawi K	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.	Nature cell biology	2008	350
plasma+or+serum	18596266	1956	Maheswaran S	Detection of mutations in EGFR in circulating lung-cancer cells.	The New England journal of medicine	2008	402
plasma+or+serum	18782861	1956	Tao RH	All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.	Journal of cell science	2008	69
plasma+or+serum	18981003	1956	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
plasma+or+serum	19047149	1956	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	65
plasma+or+serum	19058255	1956	Xia W	Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.	Molecular carcinogenesis	2009	67
plasma+or+serum	19201650	1956	Cohen EE	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.	The Lancet. Oncology	2009	52
plasma+or+serum	19276259	1956	Yung TK	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.	Clinical cancer research 	2009	99
plasma+or+serum	19351754	1956	Kuang Y	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.	Clinical cancer research 	2009	65
plasma+or+serum	19414683	1956	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	84
plasma+or+serum	19429932	1956	Mirza MA	Relationship between circulating FGF23 and total body atherosclerosis in the community.	Nephrology, dialysis, transplantation 	2009	51
plasma+or+serum	19692684	1956	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	452
plasma+or+serum	19861462	1956	Wang SC	Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.	Clinical cancer research 	2009	63
plasma+or+serum	19949019	1956	Hanrahan EO	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2010	52
plasma+or+serum	20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
plasma+or+serum	20142592	1956	Haura EB	Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	57
plasma+or+serum	20150372	1956	Raizer JJ	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.	Neuro-oncology	2010	56
plasma+or+serum	20189275	1956	Matsushita K	Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.	American journal of kidney diseases 	2010	64
plasma+or+serum	20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
plasma+or+serum	21189092	1956	de Boer RA	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.	Annals of medicine	2011	74
plasma+or+serum	21471286	1956	Hegi ME	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.	Molecular cancer therapeutics	2011	35
plasma+or+serum	21900837	1956	Goto K	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Journal of thoracic oncology 	2012	51
plasma+or+serum	21976538	1956	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	75
plasma+or+serum	22261334	1956	Han W	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.	Cancer letters	2012	64
plasma+or+serum	22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
plasma+or+serum	22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
plasma+or+serum	22520625	1956	Wang YN	Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family.	Cell and bioscience	2012	32
plasma+or+serum	22605616	1956	Goldman JW	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.	Cancer	2012	35
plasma+or+serum	22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	209
plasma+or+serum	22797485	1956	Zhao X	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.	Respiration; international review of thoracic diseases	2013	30
plasma+or+serum	22801742	1956	Doecke JD	Blood-based protein biomarkers for diagnosis of Alzheimer disease.	Archives of neurology	2012	65
plasma+or+serum	22806307	1956	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	34
plasma+or+serum	22826274	1956	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	60
plasma+or+serum	22898037	1956	Argiris A	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.	Annals of oncology 	2013	34
plasma+or+serum	23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
plasma+or+serum	23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
plasma+or+serum	23687356	1956	Rhee EP	A combined epidemiologic and metabolomic approach improves CKD prediction.	Journal of the American Society of Nephrology 	2013	40
plasma+or+serum	23888061	1956	Liu X	The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.	Journal of clinical pathology	2013	29
plasma+or+serum	24263064	1956	Douillard JY	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.	British journal of cancer	2014	33
plasma+or+serum	24429397	1956	Niewczas MA	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.	Kidney international	2014	27
plasma+or+serum	24429876	1956	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	111
plasma+or+serum	24553387	1956	Misale S	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.	Science translational medicine	2014	58
plasma+or+serum	24652789	1956	Lu JL	Association of body mass index with outcomes in patients with CKD.	Journal of the American Society of Nephrology 	2014	33
plasma+or+serum	24687921	1956	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	26
plasma+or+serum	24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
plasma+or+serum	24773774	1956	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	25
plasma+or+serum	24831979	1956	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	39
plasma+or+serum	25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
plasma+or+serum	25103305	1956	Sorensen BS	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.	Cancer	2014	32
plasma+or+serum	25122430	1956	Douillard JY	Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.	Journal of thoracic oncology 	2014	62
plasma+or+serum	25405807	1956	Wang Z	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.	PloS one	2014	31
plasma+or+serum	25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
plasma+or+serum	25594178	1956	Tan X	A kinase-independent role for EGF receptor in autophagy initiation.	Cell	2015	35
plasma+or+serum	25614492	1956	Brown MA	CKD in elderly patients managed without dialysis: survival, symptoms, and quality of life.	Clinical journal of the American Society of Nephrology 	2015	17
plasma+or+serum	25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
plasma+or+serum	25726255	1956	Higuchi C	Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes.	Metabolism	2015	20
plasma+or+serum	25769900	1956	Zhu G	Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.	The Journal of molecular diagnostics 	2015	22
plasma+or+serum	25934077	1956	Piotrowska Z	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.	Cancer discovery	2015	55
plasma+or+serum	26181014	1956	Karachaliou N	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.	JAMA oncology	2015	38
plasma+or+serum	26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
plasma+or+serum	26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
plasma+or+serum	26227959	1956	Sun W	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.	Journal of hematology and oncology	2015	25
plasma+or+serum	26229137	1956	Stubbs JR	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.	Journal of the American Society of Nephrology 	2016	27
plasma+or+serum	26295376	1956	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	25
plasma+or+serum	26459174	1956	Paweletz CP	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.	Clinical cancer research 	2016	19
plasma+or+serum	26494259	1956	Thress KS	EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.	Lung cancer	2015	39
plasma+or+serum	26577492	1956	Sueoka-Aragane N	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.	Cancer science	2016	13
plasma+or+serum	26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
plasma+or+serum	26747242	1956	Karlovich C	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).	Clinical cancer research 	2016	15
plasma+or+serum	26755650	1956	Lee JY	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).	Oncotarget	2016	16
plasma+or+serum	26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
plasma+or+serum	26867973	1956	Zheng D	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.	Scientific reports	2016	29
plasma+or+serum	26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
plasma+or+serum	26912543	1956	Torres VE	Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.	Clinical journal of the American Society of Nephrology 	2016	10
plasma+or+serum	26968708	1956	Feng K	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.	Science China. Life sciences	2016	14
plasma+or+serum	27354477	1956	Oxnard GR	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	31
rheumatic	26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
stem+cells	9831867	1956	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	109
stem+cells	15153612	1956	Chen Z	Characterization of putative stem cell phenotype in human limbal epithelia.	Stem cells	2004	116
stem+cells	16962312	1956	Nave KA	Axonal regulation of myelination by neuregulin 1.	Current opinion in neurobiology	2006	122
stem+cells	17409807	1956	Sato M	A translational view of the molecular pathogenesis of lung cancer.	Journal of thoracic oncology 	2007	79
stem+cells	17440163	1956	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	98
stem+cells	18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
stem+cells	19147502	1956	Griffero F	Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.	The Journal of biological chemistry	2009	49
stem+cells	19421880	1956	Dembinski JL	Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.	Clinical and experimental metastasis	2009	60
stem+cells	19433789	1956	O'Keeffe GC	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
stem+cells	19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
stem+cells	20049729	1956	Watt FM	Epidermal stem cell diversity and quiescence.	EMBO molecular medicine	2009	69
stem+cells	20621056	1956	Curtis SJ	Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.	Cell stem cell	2010	50
stem+cells	20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
stem+cells	20671236	1956	Zhu WZ	Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.	Circulation research	2010	59
stem+cells	20858720	1956	Mazzoleni S	Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.	Cancer research	2010	65
stem+cells	21610077	1956	Kinney SM	Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes.	The Journal of biological chemistry	2011	46
stem+cells	22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.	Oncogene	2012	52
stem+cells	22189713	1956	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	48
stem+cells	22305568	1956	Spike BT	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.	Cell stem cell	2012	56
stem+cells	22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
stem+cells	22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
stem+cells	22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
stem+cells	23149820	1956	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	49
stem+cells	23964022	1956	Giachino C	Molecular diversity subdivides the adult forebrain neural stem cell population.	Stem cells	2014	24
stem+cells	24199791	1956	Ahmad A	Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.	Journal of hematology and oncology	2013	29
stem+cells	24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
stem+cells	24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
stem+cells	24448239	1956	Luraghi P	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.	Cancer research	2014	23
stem+cells	24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
stem+cells	25895031	1956	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	32
stem+cells	26267324	1956	Riquelme I	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.	Oncotarget	2015	18
stem+cells	26330164	1956	Caruso HG	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.	Cancer research	2015	36
stem+cells	26434585	1956	Schneider MR	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.	Oncogene	2016	12
stem+cells	27117702	1956	Lin S	The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.	Molecular cell	2016	23
toxicology+or+toxic+or+toxin	9041202	1956	Relf M	Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.	Cancer research	1997	128
toxicology+or+toxic+or+toxin	15269313	1956	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	891
toxicology+or+toxic+or+toxin	16014882	1956	Shepherd FA	Erlotinib in previously treated non-small-cell lung cancer.	The New England journal of medicine	2005	1010
toxicology+or+toxic+or+toxin	16467544	1956	Bonner JA	Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2006	811
toxicology+or+toxic+or+toxin	17192538	1956	Geyer CE	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	The New England journal of medicine	2006	587
toxicology+or+toxic+or+toxin	18403491	1956	Sampson JH	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.	Neuro-oncology	2008	54
toxicology+or+toxic+or+toxin	19027483	1956	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	258
toxicology+or+toxic+or+toxin	19201650	1956	Cohen EE	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.	The Lancet. Oncology	2009	52
toxicology+or+toxic+or+toxin	19692684	1956	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	452
toxicology+or+toxic+or+toxin	20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	979
toxicology+or+toxic+or+toxin	21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
toxicology+or+toxic+or+toxin	21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
toxicology+or+toxic+or+toxin	23883922	1956	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	116
toxicology+or+toxic+or+toxin	24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
toxicology+or+toxic+or+toxin	24831979	1956	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	39
toxicology+or+toxic+or+toxin	24867380	1956	Liu S	Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.	Cancer treatment reviews	2014	28
toxicology+or+toxic+or+toxin	25923549	1956	Jänne PA	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.	The New England journal of medicine	2015	228
toxicology+or+toxic+or+toxin	25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
toxicology+or+toxic+or+toxin	26045340	1956	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	52
toxicology+or+toxic+or+toxin	26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
